University of Central Florida

STARS
Electronic Theses and Dissertations
2017

Chaperonin Containing TCP1 (CCT) as a Target for Cancer
Therapy
Ana Carr
University of Central Florida

Part of the Biotechnology Commons, and the Cancer Biology Commons

Find similar works at: https://stars.library.ucf.edu/etd
University of Central Florida Libraries http://library.ucf.edu
This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted
for inclusion in Electronic Theses and Dissertations by an authorized administrator of STARS. For more information,
please contact STARS@ucf.edu.

STARS Citation
Carr, Ana, "Chaperonin Containing TCP1 (CCT) as a Target for Cancer Therapy" (2017). Electronic Theses
and Dissertations. 6032.
https://stars.library.ucf.edu/etd/6032

CHAPERONIN CONTAINING TCP1 (CCT) AS A
TARGET FOR CANCER THERAPY

by

ANA CAROLINA CARR
B.S. University of Central Florida, 2012

A dissertation submitted in partial fulfillment of the requirements
for the degree of Doctor of Philosophy
in the Cancer Division
of the Burnett School of Biomedical Sciences
in the College of Medicine
at the University of Central Florida
Orlando, Florida

Fall Term
2017

Major Professor: Annette Khaled

© 2017 Ana Carolina Carr

ii

ABSTRACT
Treatments for aggressive cancers like triple negative breast cancer (TNBC) and
small-cell lung cancer (SCLC) have not improved and remain associated with debilitating
side effects. There is an unmet medical need for better, druggable targets and improved
therapeutics. To this end, we investigated the role of Chaperonin-Containing TCP1
(CCT), an evolutionarily conserved protein-folding complex composed of eight subunits
(CCT1-8), in oncogenesis. Our laboratory was the first to report that the CCT2 subunit is
highly expressed in breast cancer and could be therapeutically targeted. To determine
whether CCT is a marker of disease progression in other cancers, we analyzed CCT2
gene expression in liver, prostate and lung cancer, using publicly available genetic
databases, and confirmed findings by assessing CCT2 and client proteins, like STAT3, in
tumor tissues by immunohistochemistry. We found that CCT2 was high in all cancers,
especially SCLC, and correlated with decreased patient survival. We tested CT20p, the
peptide therapeutic developed by our laboratory to inhibit CCT, on SCLC and primary
lung cells, finding that CT20p was cytotoxic to SCLC cells. Since SCLC currently lacks
targeted therapeutics, our work yielded a new targeted agent that could improve lung
cancer mortality. To establish a mechanism of action for CT20p, we partially knocked
out CCT2 in TNBC cells, which decreased tumorigenicity in mice and reduced levels of
essential proteins like STAT3. To confirm, we overexpressed CCT2 in non-tumorigenic
cells and conferred tumor-like characteristics such as increased migration and elevated
STAT3. These studies positioned us to develop and validate a strategy for discovery of
new small molecule inhibitors of CCT. We thus advanced the field of cancer research by
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demonstrating that CCT could have diagnostic potential for cancers, such as SCLC and
TNBC, that are a significant cause of human death and showed that targeting CCT is a
promising therapeutic approach.
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CHAPTER 1:INTRODUCTION

Preface

This chapter was composed entirely by A.C.C. Comments from A.K. were
incorporated into the final version presented here.
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The Burden of Cancer

Cancer is the second leading cause of death in the United States and accounts for
nearly 1 in every 4 fatalities [1, 2]. For the year of 2017, it is estimated that 600,920
people will die due to cancer in the United States alone (Table1), that’s equivalent to
1,650 deaths per day [3]. In regards to cancer incidence, it is estimated that 1,688,780
people will be diagnosed with cancer in 2017, that equates to over 4,600 people being
diagnosed with cancer daily [3]. The most commonly diagnosed type of cancer in women
is breast cancer. In the U.S., the chances of a woman being diagnosed with breast cancer
during her lifetime is 1 in 8 or 12.4% [4]. That’s an increase from the 9.09% 1970’s rate.
Part of this increase is due to longer life expectancy in addition to increased incidence
[4]. The most commonly diagnosed type of cancer in men is prostate cancer. The lifetime
risk of a man developing prostate cancer is 11.6% based on 2012-2014 data. Overall, rate
of cancer incidence is 20% higher in men than in women, while rate of cancer fatalities is
40% higher [5]

Lung Cancer
Lung cancer is the deadliest type of cancer in the United States and Worldwide,
being responsible for more deaths than prostate, breast and colorectal cancer combined
[6]. There are two major classes of lung cancer: non-small cell lung cancer (NSCLC) and
small cell lung cancer (SCLC). NSCLC is responsible for more than 80% of cases and its
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further

subdivide

into

three

subtypes

based

on

histological

characteristics:

adenocarcinoma (AdC), squamous cell carcinoma (SqCLC) and large cell carcinoma
(LCC). SCLC accounts for 10 to 15% of cases. SCLC is more aggressive, faster
spreading, and more likely to recur than NSCLC. It is associated with a 5-year survival
rate of only 6%, compared to 21% for NSCLC [6]. The 5- year survival rate of lung
cancer is only 17.8%, which is much lower than the 90.5% and 99.6% survival rates for
breast and prostate cancer, respectively [2]. Frequently, the symptoms associated with
lung cancer do not appear until the cancer is advanced, a factor that contributes to the
severity of this disease. Over 50% of lung cancers are only detected after the tumor has
metastasized from the primary site, and the 5-year survival rate for these cases are 4%
[2]. SCLC is a carcinoma of neuroendocrine origin and it is characterized by aggressive
behavior, fast growth and high metastatic spread [7]. Treatments for SCLC include
cisplatin and etoposide and although about 75% of tumors respond to chemotherapy, only
25% show complete response and most patients experience disease relapse [8, 9].
Attempts to improve outcome using combination therapy or prolonged regimens, have
not been successful.

Breast Cancer
Breast cancer is the second leading cause of death in women [3]. There’s a 12.4%
risk of a woman developing breast cancer during her lifetime, that is one in eight women
will be diagnosed with breast cancer [1, 6]. About 90% of deaths caused by breast cancer
are due to metastatic disease [10]. Metastasis occurs when tumor cells leave the primary
3

site and invade distant, vital organs such as lungs, brain and liver, in which case,
currently available chemotherapeutics are no longer effective. Breast cancer is a
heterogeneous disease and while certain subtypes of breast cancer, such as ER+, benefit
from hormone therapy and are associated with better prognosis, subtypes such as triple
negative breast cancer (TNBC) are associated with lower survival rate and poor prognosis
[11]. TNBC affects 17% of breast cancer patients and it is characterized by the absence of
estrogen (ER) and progesterone (PR) hormone receptors, as well human epidermal
growth factor receptor 2 (Her2) so patients diagnosed with TNBC cannot benefit from
hormone therapies or Her2 inhibitors [11]. TNBC is the most aggressive form of breast
cancer, marked by genomic instability, heterogeneity, high incidence of drug resistance,
high recurrence rates and increased risk of metastasis. The aggressive biology of TNBC
and the lack of approved targeted agents have contributed to the challenges associated
with treating this disease successfully [12].

The challenge

Current treatment strategies for patients diagnosed with cancer include surgery, radiation
therapy and chemotherapy. Surgery is usually recommended for patients with solid
tumors that are limited to one area and it is not an option in patients with metastatic
disease. Radiation therapy can be given with curative, palliative intent or as a
prophylactic measurement as exemplified by small cell lung cancer patients who often
4

receive prophylactic cranial irradiation to reduce the risk of brain metastases [Takahashi,
2017 #165]. Traditional chemotherapeutic agents, or cytotoxics, can target the cell cycle
in a specific manner, being most effective during S or M phase, or in a non-specific
manner (independent of cell cycle phase). Side effects associated with traditional
chemotherapy are debilitating and often have a negative impact on the patient’s quality of
life. Additionally, due to tumor heterogeneity, positive selection of drug-resistant tumor
subpopulation tumor may lead to tumor recurrence. Resistance to chemotherapies and
targeted therapies limits the effectiveness of current cancer treatments Oncology drugs
that go into clinical trial have poor success rates, being three times lower than that of
cardiovascular disease [13]. There is a fundamental flaw in the way we have looked at
cancer treatments so far. How can we redefine our approach?

The dynamic duo

CT20p: the rationally developed peptide
CT20p is an amphipathic peptide derived from the last twenty amino acids in the
C-terminus of the pro-apoptotic Bax [14] (Fig. 1). CT20p had cytotoxicity activity that
was independent of the parent protein or Bcl-2 overexpression and caused cytoskeletal
disorganization, loss of adhesion, and cell death [14, 15]. CT20p is membrane
impermeable but can be encapsulated for delivery to cancer cells in nanoparticles (NPs)
made from a hyperbranched, polyester polymer (HBPE) [16, 17]. The resulting HBPE-
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CT20p has increased serum half-life in addition to having the potential of being modified
to contain different groups, which allows targeting of tumor cells. In animal models of
breast and prostate cancer, treatment with CT20p-NPs caused significant tumor
regression [18, 19]. In order to determine the target of CT20p, a pull down experiment
was performed and the target proteins were subjected to mass spectroscopy analysis (Fig.
2). The top results from the pull down experiment are shown in Table 2 and indicate that
CT20p interacts with 7 out 8 subunits (numbers 5-11 on the list) of the chaperonin
containing TCP1 (CCT). Transient overexpression of CCT2 (denoted CCTβ in figure 3)
in cells with low CCT2 levels, increased susceptibility to the peptide (Fig. 3).
Conversely, silencing the CCT2 gene in cells highly susceptible to the peptide, decreased
susceptibility [18].

Figure 1: Amino acid sequence and structure of CT20p
This figure illustrates the amphipathic nature of CT20p. Polar residues are shown in
yellow, hydrophobic residues are shown in light grey and basic residues are shown in red.
CT20p structure was rendered using PyMol by the author.
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Figure 2: Biotin-CT20p pull down
(A) Biotin-CT20p was used to pull down interaction proteins in MCF-10A and MDAMB-231 lysates. Lysates were run on SDS-PAGE, and the gel was silver stained to
visualize bands. Molecular weights (MW) indicated are in kDa. Four bands, indicated by
boxes, were excised from MDA-MB-231 Biotin-CT20p and biotin pull downs and
analyzed by mass spectrometry. All lanes presented were originally run on the same gel,
but have been rearranged for clarity in this figure. (B-C) To analyze true binding to
CT20p, proteins also identified in the biotin pull down or control gel sample were
excluded. This resulted in 114 true binding partners in the 50 kDa band (B), and 81 in the
90 kDa band (C). (D-E) As a control for the “in-cell” pull down, DiI dye encapulated in
HBPE-nanoparticles was delivered to viable MCF-10A (D) and MDA-MB-231 (E) cells,
followed by cell lysis and recovery of bound proteins. CCTβ and p38 were detected by
Western blot - Reprinted from Clinical Cancer Research, 2016, Volume 22, Issue 17,
Rania Bassiouni et al., “Chaperonin Containing-TCP-1 Protein Level in Breast Cancer
Cells Predicts Therapeutic Application of a Cytotoxic Peptide”, with permission from
AACR
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Figure 3: CCT overexpression increases the susceptibility of MCF-10A cells to
CT20p
(A) MCF-10A and MCF-10A (CCT) cells were subjected to a migration assay for 20
hours. The premigration area is outlined. (B) MCF-10A cells were transfected to
overexpress CCTb are denoted here as MCF-10A (b). The levels of CCT subunits were
examined by immunoblotting in these cells, as well as in MCF-10A and MCF-10A
(CCT) cells. p38 MAPK is used as a loading control. (C) level of CCTb relative to total
protein was quantified in the three MCF-10A variants. (D) MCF-10A variants were
treated with CT20p at a dose of 75 mg/mL for 24 hours. Cell death discrimination was
determined by staining with Sytox AADvanced and F2N12S, followed by flow
cytometry. The viable cells are in the lower-right quadrant, and their percentage is
displayed in bold. As a control, mock-transfected MCF-10A were similarly analyzed. E,
viability data of the MCF-10A variants was quantified. = *** = p<0.001, **** =
p<0.0001- Reprinted from Clinical Cancer Research, 2016, Volume 22, Issue 17, Rania
Bassiouni et al., “Chaperonin Containing-TCP-1 Protein Level in Breast Cancer Cells
Predicts Therapeutic Application of a Cytotoxic Peptide”, with permission from AACR.
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CCT: the intracellular target
Chaperones are a group of proteins essential for maintaining proteostasis by
stabilizing other proteins and helping them reach their native conformation [20].
Chaperonins (a class of chaperones) are formed by two rings stacked back-to-back,
forming a central cavity in which unfolded client proteins are sequestered into and can
reach native conformation isolated from the cytosol [21]. Chaperonins are further
subdivided into Group I, present in bacteria, mitochondria and chloroplast, and Group II,
found in archaea and eukaryotes [21]. The eukaryotic chaperonin containing TCP1
(CCT), also known as TriC, is a type II chaperonin composed of two stacked rings, each
ring consisting of eight paralogous subunits (Fig. 4). Subunits of the mammalian CCT are
named using Greek letters (CCTα - CCTθ) and subunits in yeast are denoted using
numbers (CCT1-CCT8). Subunits range from 50kDa-60kDa [21, 22].
CCT subunits are structural homologues and each subunit comprises an apical
substrate binding domain, an equatorial ATP binding domain and an intermediate domain
linking the other two domains (Fig. 5). CCT’s ATP binding domain is extensively
conserved among the subunits, in contrast with the apical substrate binding domain,
which is the most convergent [23]. This 1MDa complex folds about 10% of the
eukaryotic proteome in a ATP dependent manner [24]. The nascent peptide is sequestered
into the cavity of CCT partially or entirely where energy derived from ATP hydrolysis
allows the substrate to achieve native conformation [25].
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Figure 4: Overall structure of CCT
Structure of yeast CCT showing the closed conformation of the chaperonin and top view
showing the arrangement of all eight paralogous subunits. PDB accession number 4V94.
Image downloaded and rendered in PyMol by the author [21]
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Figure 5: Ribbon diagram of bovine CCT2 subunit
General architecture of CCT subunits exemplified by CCT2 from bos tauros. The
substrate binding apical domain (teal) is linked to the equatorial, ATP binding domain
(fuchsia) by the intermediate domain, a flexible linker that allows CCT transition from
open (substrate binding) to closed (ATP binding) forms. Image generated by A.C.C.
using structure PDB number 3KTT
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CCT clients
Although there is much to be learned in regards to CCT’s substrate specificity, a
study have showed that about 40% of CCT’s substrates are essential and about 90% are
oligomeric complexes [24]. Studies on CCT client’s diversity using NMR, modeling, XLMS and mutagenesis suggest that client proteins contact CCT subunits in their apical
domain on the same loop [26]. The eight human CCT subunits share 30% homology and
are most divergent at the apical domain, indicating subunit specialization acquired
through evolution. Cytoskeletal proteins such as actins and tubulins, can only reach their
native conformation if CCT mediated [22]. Notably, many of CCT’s client proteins are
involved in oncogenesis, including Von Hippel-Lindau (VHL), p53, cyclin B and E,
Cdc20, Myc and Stat3 [27, 28]. Von Hippel-Lindau protein (VHL) is a tumor suppressor
E3 ligase, crucial to the hypoxia response pathway [29]. Loss of function mutations have
been associated with hemangioblastomas, retinal angiomas, clear cell renal cell
carcinoma, pheochromocytoma; pancreatic neuroendocrine tumor [27, 30]. VHL was the
first non-cytoskeletal protein shown to be a CCT client [31]. The tumor suppressor gene
TP53 is the most commonly mutated gene in cancers and recent evidence indicates p53
needs CCT for proper folding [32, 33]. CCT also folds and regulates many cell cycle
regulatory proteins such as Cyclin E [34], Cyclin B and Cdc20 [35, 36]. Myc is an
oncogene involved in the onset of many cancers [37], also folded by CCT. Signal
transducer and activator of transcription 3 (Stat3) transduces signals of over 40 peptide
hormones from the cell surface to the nucleus and acts as an oncoprotein in several
cancers types [28, 38]. Taken together, this indicates that CCT is a key regulator of many
proteins necessary for the development of several cancers.
12

CCT levels in cancer
In addition to assisting in the folding of many proteins involved in oncogenesis
and cancer progression, CCT levels are elevated in many cancer types. As an example,
the CCT8 subunit was upregulated in hepatocellular carcinoma and played an important
role in the proliferation of these cells [39]. A similar correlation was observed with CCT1
(TCP1) and CCT2 in both hepatocellular carcinoma and colonic carcinoma [40] and with
CCT2 in colorectal carcinoma. CCT1 and CCT2 may be upregulated by driver oncogenes
that are responsible for tumorigenesis in breast cancer [41]. Our own published studies
provided evidence that CCT2 is significantly overexpressed in invasive ductal breast
carcinoma (IDC) and in TNBC cell lines, like MDA-MB-231 [18], as well as prostate
cancer cell lines [19], suggesting the CCT2 levels could correspond to increased disease
severity. The elevated levels of CCT subunits in cancer is important in two aspects.
Firstly, CCT levels can be used as a biomarker in the clinical setting for early diagnosis
of multiple types of cancer as well as a potential marker of disease severity. Secondly,
due to its elevated levels in cancer cells compared to normal ones, CCT is also a
promising target for cancer therapy.
We suggest that by targeting multiple aspects involved in cancer progression
(versus a single mutation or pathway) the probability of recurrence and resistance is
greatly diminished. Cancer cells have higher demand for many of CCT’s client proteins,
therefore CCT inhibition will prevent the proper folding of key cancer related proteins,
halting cancer progression.
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Table 1: Estimated new cases and deaths due to cancer for 2017

Estimated New Cases
Males

Estimated Deaths

Primary site

Total

Females

All sites

1,688,780

836,150

852,630

600,920

318,418

282,500

Breast

255,180

2,470

252,710

41,070

460

40,610

Prostate
Lung and
Bronchus

161,360

161,360

26,730

26,730

-

222,500

116,990

155,870

84,590

71,280

105,510

Table reproduced from numbers published in Cancer statistics, 2017 [5]
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Total

Males

Females

Table 2: Proteins identified by mass spectrometry to interact with CT20p

Reprinted from Clinical Cancer Research, 2016, Volume 22, Issue 17, Rania Bassiouni et al., “Chaperonin Containing-TCP-1
Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide”, with permission from AACR
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CHAPTER 2: TARGETING THE CHAPERONIN CONTAINING
TCP1 (CCT) AS A THERAPEUTIC FOR SMALL CELL LUNG
CANCER

Preface

The work presented in this chapter has material accepted for publication in
Oncotarget, Impact Journals, LLC expected publication month is November 2017. The
material is reprinted here under the Creative Commons CC BY NC license which permits
non-commercial use, distribution and reproduction in any medium, of the original work

Ana C. Carr, Amr S. Khaled, Rania Bassiouni, Orielyz Flores, Daniel
Niernenberg, Hammad Bhatti, Priya Vishnubhotla, J. Manuel Perez,
Santimukul Santra, and Annette R. Khaled.. Targeting the Chaperonin
Containing TCP1 (CCT) as a Therapeutic for Small Cell Lung Cancer
Oncotarget
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Introduction

Cancer remains a leading cause of death, with breast, lung, prostate, and
colorectal among the top four cancers in terms of new cases diagnosed and estimated
deaths [42]. Most cancer-related deaths are due to metastatic disease, when the primary
cancer spreads to vital organs like the brain, bone, or liver. A significant impediment to
finding effective treatments or better ways to detect and diagnose cancers, especially
metastatic cancers, is tumor heterogeneity. Genomic instability, together with selection
pressures from the tumor micro-environment, are among the factors that produce genetic
and phenotypic differences in patients’ tumors and even within the same tumor (intratumor heterogeneity). A case in point is small cell lung cancer (SCLC). SCLC accounts
for about 15% of lung cancer cases and is characterized by genetic alterations and a high
proliferative index as well as early metastatic spread [8]. SCLC is an aggressive disease,
and while responsive to initial treatments, patients later succumb to the disease, which is
associated with a high rate of relapse and recurrence [43, 44]. SCLC can be further
classified as limited stage (LS-SCLC) if the disease is confined to one hemithorax and
regional nodes, or as extensive disease (ES-SCLC) if the cancer has spread to distant sites
[45, 46]. This classification helps determine the treatment plan for SCLC patients,
whether surgery and/or prophylactic cranial irradiation (PCI) are recommended. The
first-line treatment for any stage of SCLC is etoposide-platinum based chemotherapy;
however, patient survival decreases upon disease recurrence, largely due to the
development of chemoresistance [9, 11, 43]. Although SCLC is a good candidate for
targeted therapies, clinical trials testing new targeted chemotherapeutics for SCLC
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patients have been unsuccessful. As an example, a recent clinical trial using
bevacizumab—an angiogenesis inhibitor targeting the vascular endothelial growth factor
(VEGF)—in combination with etoposide-platinum based chemotherapy for SCLC
patients, concluded that the addition of bevacizumab did not improve patient overall
survival [47]. In comparison, in non-small cell lung cancer (NSCLC) patients, modest
results were achieved with angiogenesis inhibitors like bevacizumab when used in
combination with chemotherapeutics to treat metastatic patients [48, 49]. While there is
renewed hope of developing new cancer drugs, especially with the recent focus on
immunotherapies, the challenges of achieving a molecularly targeted treatment that
provides real benefit for patients with cancers like SCLC are substantial. Central to these
challenges is the need to identify druggable molecular alterations through a better
understanding of the basic biology underlying these aggressive cancers.
The molecular landscape underlying the heterogeneity of cancers like SCLC is far
from understood and complicates cancer drug discovery. While SCLC has not undergone
extensive molecular subtyping, it is characterized by a high mutation rate and genomic
instability. Inactivation of TP53 and RB1 [50], along with alterations of MYC, NOTCH,
and the PI3K/AKT/mTOR pathways, are among the key genetic changes associated with
SCLC [51]. Other genes less frequently mutated in SCLC include EGFR [52], KIT [53],
MET [54, 55], and heat shock proteins [56]. These genes are also commonly mutated in
other cancers. [57]. Using targeted agents to inhibit these pathways is the goal of many
studies, but recent findings suggest that single target agents are less effective, and that
combination therapies, hitting multiple pathways, are more successful in preventing
cancer relapse and drug resistance in patients [58, 59]. A drawback for combination
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approaches, however, is the potential for increased drug-related off-site toxicities. A
rational approach would be to inhibit protein-folding, which could impact multiple
pathways while using a single inhibitory agent. Chaperonin-containing TCP-1 (CCT) or
T-complex 1 ring protein (TRiC) is an evolutionarily conserved macromolecular complex
involved in folding about 10% of the cell proteome [21]. Many of the gene products
deregulated in cancers such as SCLC (e.g., MYC, TP53, CCNE, KRAS, HSP90, ESR1,
and NOTCH) are CCT client proteins [60], suggesting a role for the involvement of CCT
in the development of cancer, driving the need to better understand its contribution to
malignant transformation.
Collective evidence suggests that CCT may be upregulated in a broad range of
cancers. CCT is a hetero-oligomeric complex composed of two rings formed by eight
subunits [61]. Each CCT subunit, named CCT1-8 (or CCT-θ), is found at a fixed
position in the ring [21]. Protein folding occurs within a central chamber formed by the
rings and is mediated through the opening and closing of a lid structure in an ATPdependent fashion [62, 63]. A study examining CCT and its activity in cancer cell lines
revealed that while these cell lines had varying reliance on the protein-folding activity of
CCT, it was more impactful in cancer cells than in normal cells [64]. As an example, in
hepatocellular (HCC) carcinoma, the CCT8 subunit was upregulated and played an
important role in the proliferation of these cells [39]. A similar correlation was observed
with CCT1 (TCP1) and CCT2 in both hepatocellular carcinoma and colonic carcinoma
[40], as well as with CCT2 in colorectal carcinoma. In breast cancer, CCT1 and CCT2
may be upregulated by driver oncogenes that are responsible for tumorigenesis [41]. Our
own published studies provided evidence that CCT2 is significantly overexpressed in
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invasive ductal breast carcinoma and in triple-negative breast cancer (TNBC) cell lines,
like MDA-MB-231 [18], as well as prostate cancer cell lines [19]. This suggests that the
CCT2 levels could correspond to increased disease severity.
The elevated expression of different CCT subunits in cancer is intriguing on two
fronts. First, CCT levels may be useful as a biomarker in clinical settings. Potentially,
CCT could be detected as an early diagnostic marker in cancers such as SCLC. Or it
could be used for the diagnosis of disease severity in cancers like breast cancer, in which
levels of CCT2 correlated with disease progression, as we have previously demonstrated
[18]. Second, CCT is a promising target for cancer therapy, as depletion of CCT in cancer
cells caused cell cycle arrest and growth inhibition [39, 41]. In previous studies, we
showed that an amphipathic peptide called CT20p, derived from the last twenty amino
acids of Bax, had cytotoxicity activity that was independent of the parent protein or Bcl-2
overexpression and caused cytoskeletal disorganization, loss of adhesion, and cell death
[14, 15]. CT20p, while being membrane impermeable, can be readily encapsulated for
delivery to cancer cells in nanoparticles (NPs) made from a hyperbranched, polyester
polymer [16, 17]. In animal models of breast and prostate cancer, treatment with CT20pNPs caused significant tumor regression [18, 19]. The mechanism of action of CT20p is
likely inhibition of CCT, as overexpression or deletion of the CCT2 subunit altered the
capacity of the peptide to kill cells [18]. In the work presented herein, we examined the
protein levels of CCT in tissue samples of liver, prostate, colon, and lung cancer to
determine whether CCT subunits were highly expressed in these cancers. We also sought
to determine whether inhibition of CCT through treatment with CT20p could impact CCT
client proteins needed for cancer progression. To that end, we focused on STAT3, since
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this transcription factor is a CCT client protein [28], is constitutively active in many
tumors [38], and is a predictor of poor prognosis in cancer [38, 65]. Our analysis revealed
SCLC to be a promising model to study the role of CCT in cancer, as well as a likely
candidate to benefit from CCT-targeted therapy.

Materials & Methods
Immunohistochemistry
Tissue microarrays (TMAs) used in this study were obtained from US Biomax,
Inc. Their catalog numbers are as follows: CO484a (colonic carcinoma), PR803b and
PR631 (prostate carcinoma), BC03118 (hepatocellular carcinoma), LC726b, LC802a,
LC802c, and BC041115a (lung carcinomas) and BN501 (normal tissue array). Each
TMA contained varied numbers of patient tissue cores as well as normal tissue
corresponding to the specific cancer type being analyzed. Please refer to Table 3 and 4
for the number of samples per cancer type. Information about the tissue type, TNM score,
tumor grade, and stage were provided with the samples. ΤΜΑs were stained for CCT2
using anti-CCTβ antibody (LS-B4861; LifeSpan Biosciences). TMA LC802c was stained
in parallel for CCT2 and Stat3 (anti-Stat3 antibody ab32500; Abcam).

Primary

antibodies were diluted 1:100 in Antibody Diluent (Leica). Staining of tissue arrays was
performed by a Bond-Max Immunostainer (Leica), with an epitope retrieval buffer of
EDTA pH 9.0 (Leica). Polymer Refine Detection reagents (Leica) were used, which
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include a hematoxylin counterstain. Image acquisition and scoring of staining was
performed by a surgical pathologist as previously published [18]

Cell lines and culture condition
NCI-H1882 (ATCC CRL-5903), NCI-H1048 (ATCC CRL-5853), NCI-H1105
(ATCC CRL-5856) and NCI-H719 (ATCC CRL-5837) were cultured in HITES medium
supplemented with 5% FBS (Gemini). NCI-H1417 (ATCC CRL-5869) was cultured in
RPMI-1640 in 10% FBS.

MCF 10A (ATCC CRL-10317) cells were cultured in

Mammary Epithelial Cell Growth Media using MEGM bullet kit (Lonza). THLE-2
(ATCC CRL-2706) cells were cultured in Bronchial Epithelial Cell Growth Media using
BEGM bullet kit (Lonza) without the supplied epinephrine, supplemented with an extra 5
ng/mL EGF (Corning), 70 ng/mL phosphoethanolamine (Sigma) and 10% FBS. AC16
Human Cardiomyocyte Cell Line (Millipore-Sigma) was cultured in AC16 expansion
medium [66]. All media contained 1% antibiotic antimycotic solution (Corning). Cells
were grown in a humidified 37 incubator with 5% carbon dioxide. All experiments with
listed cell lines were performed within 4 months of receiving them using low passage
number cells. Viability was routinely assessed by trypan blue exclusion (Gibco). Table 5
provides additional cell line information as well as the lot number of all cells lines used in
this study.
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Reagents
CT20p

(VTIFVAGVLTASLTIWKKMG)

was

commercially

synthesized

(Biopeptide Co., Inc) at >98% purity, with the N- and C- terminals capped with acetyl
and amine groups, respectively.

For cellular delivery, CT20p was encapsulated in

hyperbranched polyester nanoparticles (HBPE-NPs) as previously described [14, 15, 17].
Typically, a peptide loading of 0.15 µg CT20p to 1 mg polymer is achieved. Stat3
inhibitor VI S31-201 (Calbiochem) was purchased already in solution.

Treatments
Cytotoxicity experiments: the indicated adherent cell lines were seeded in 96 well
plates at the recommended seeding density and treated at 70-80% confluency. Suspension
cell lines were transferred to a 96 well plates in 70% of final well volume, using fresh
medium. Adherent cells were treated by replacing the well medium with medium
containing CT20p-HBPE-NPs or Stat3 inhibitor VI at final treatment concentration.
Suspension cells were treated in 30μLs (3.34X concentration), 24 hours after being
transferred to 96 well plate. The concentrations selected for CT20p-HBPE-NPs
treatments were 75 μg nanoparticle/mL 150 μg nanoparticle/mL. The concentrations of
Stat3 inhibitor VI (S31-201) used were 50μM and 100μM, based on product description
overview regarding effective concentration of < 100μM (Calbiochem, 573130).
NCIH1882 cells were treated for 16 hours with 150 μg/mL CT20p-HBPE-NPs, in
parallel with untreated control, which received medium only. Cells were lifted, washed in
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1XPBS and frozen at -80ºC until lysate preparation. NCI-H1048 cells were treated for 6
hours before being lifted for lysate preparation.

Measuring cell viability
Cytotoxicity of cells treated with CT20p-HBPE-NPs or Stat3 inhibitor VI was
determined by adding Calcein-AM and ethidium homodimer (Live/Dead Thermofisher)
48 hours post treatment and measuring signal intensity using GFP and TexasRed filter
cubes respectively. Signal intensity and image acquisition were obtained using Cytation5
(Biotek) and Gen5 software. Per well, three distinct, non-overlapping areas were imaged
using a 4X phase objective without and with each appropriate filter. Because suspension
cells grow in clusters, determining cell number using the “cellular analysis” feature is
suboptimal. We use image analysis to determine GFP and TexasRed mean fluorescent
intensity. Threshold values were employed when appropriate to eliminate background
signal. All the data points generated per condition are averaged and used to calculate the
ratio between intensity from GFP (live cells) and TexasRed (dead cells). Only
unprocessed images were used for data analysis. Representative images are shown on
figures.

Immunoblotting
Cell pellets used to make protein lysates were washed in 1X PBS (Corning) and
frozen at -80̊ C for at least 1 hour prior to lysis. Lysates were obtained by quickly adding
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ice cold NP-40 Lysis Buffer (50mM K+HEPES pH 7.5, 150mM NaCl, 1% NP-40, 1mM
EDTA) with freshly added Halt protease inhibitor (Thermo, 78438) immediately after
pellets were removed from the -80̊ C. Lysis took place on ice for 20 minutes with gentle
and intermittent vortexing intervals. Lysates were cleared by centrifuging at 12,000 x g
for 10 minutes, at 4̊ C. Soluble lysates were stored at -20̊ C for no longer than 3 months.
Freeze/thaw cycles were minimized to avoid protein precipitation and degradation.
Proteins in the lysates were resolved by SDS-PAGE and transferred to Immobilon-FL
PVDF membrane (Millipore IPFL00010). Prior to blocking, membranes were stained for
total protein using Revert (LI-COR) and imaged on Odyssey (LI-COR) using the 700
channel. After blocking, blots were probed with primary antibodies against CCT2 (antiCCTβ, Millipore), CCT4 (anti-CCTΔ, Abcam), CCT5 (anti-CCTε, Abcam), and STAT3
(anti-Stat3, Abcam), followed by 1-hour incubation with secondary antibodies IRDye
800CW and/or IRDye 680CW (LI-COR) at a 1:10000 dilution. Bands were visualized by
NIR fluorescence detection using Odyssey (LI-COR). Relative protein quantification was
performed with Image Studio software (LI-COR). The signal obtained for proteins of
interest were normalized to total protein content using Revert (LI-COR) image as
follows: first, total protein quantification was performed using the 700nm channel, using
all the protein transferred onto the blot after Revert staining. Second, lane normalization
factor (LNF) was calculated by dividing the signal of each lane by the signal from the
lane with highest signal. Third, target signal was determined. Normalization was
performed by dividing the signal from each target by the LNS. Immunostaining was
performed with a minimum of two biological replicates and at least three technical
replicates per target.
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Statistical analysis
Experiments were performed at least three times, in duplicates or triplicates,
where appropriate. Data representative of experiments were selected for this publication.
TMA data is expressed as means and standard deviation, whereas blots and Live/Dead
assay data is represented as means and standard error. One-way ANOVA was used to
compare mean scoring between the different groups defined by various tissue parameters
as well as signal intensity ratio in treated cells. Tukey’s multiple comparison test was
used to compare significance between individual groups. For CT20p treatment analyzed
by immunoblot, unpaired, two-tailed t-test was used to calculate significance between
untreated and treated samples. Calculations were performed with GraphPad Prism
software (GraphPad). Statistical significance was defined as p < 0.05. Datasets generated
in the current study are available in the Kaplan-Meier Plotter (KMPlot) repository [67,
68] at http://kmplot.com/analysis/index.php?p=service&cancer=breast.
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Results

CCT2 is overexpressed in lung cancer patient tumors and correlates with decreased
survival.
CCT is a macromolecular complex composed of eight subunits, which we will
refer to by number (CCT1-8) hereinafter. Our previous studies with breast cancer [18]
revealed that the CCT2 subunit was overexpressed in tumor tissues as compared to
normal tissues, was increased with advanced disease, and was inversely correlated with
patient survival.

To determine whether CCT2 was elevated in other cancers, we

evaluated CCT2 protein levels in several human tissue microarrays (TMAs) for lung,
colon, hepatocellular, and prostate carcinomas by immunohistochemistry (IHC). We
found that lung, liver, and prostate tissues had significantly higher levels of CCT2 as
compared to matched normal tissue (Fig. 6A,B, and E,F Fig. 7A,B). Our findings for
colon cancer were inconclusive due to high background staining of normal colon tissue
(Fig. 6I). In liver carcinomas, CCT2 levels were higher in both subtypes analyzed (HCC
and cholangiocellular carcinomas) as compared to normal hepatic tissue (Fig. 6A-B).
This difference was statistically significant (p<0.05) in HCC. We also analyzed HCC
according to grade, as high grade HCC is associated with poorer prognosis [69], and
observed a progressive increase in CCT2 staining with increasing grade (Fig. 6A). In
prostate adenocarcinoma, we observed significantly increased levels of CCT2 as
compared to normal prostate tissue (Fig. 6E). Because increased stage indicates higher
severity of disease and poorer prognosis, we also analyzed CCT2 levels in prostate cancer
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by stage and observed a trend of increasing CCT2 staining with increasing stage (Fig.
6E). Mining databases like The Cancer Genome Atlas (TCGA) and the Human Protein
Atlas confirmed our findings that high expression of CCT2 occurs in liver and prostate
cancer and is associated with unfavorable prognosis (Fig. 6C,D and G,H). However, in
colon cancer, high levels of CCT2 were associated with improved prognosis, although
this result was not statistically significant (Fig. 6J).
We next assessed the levels of CCT2 in various subtypes of lung cancer by
evaluating staining intensity in 236 tissue microarray cores containing cases of
adenocarcinoma, carcinoid, SCLC, and squamous cell lung carcinoma (SqCLC) (Table
3). This was then compared to normal lung tissue. All lung cancer subtypes examined had
significantly higher levels of CCT2 as compared to normal tissue (Fig. 7A).
Representative images of CCT2 staining in normal lung tissue, SqCLC, and SCLC are
provided in Figure 7B. We selected SqCLC and SCLC to study in greater detail because
together, these two lung cancer types represent 35%-45% of all cases [3] and both scored
significantly higher than normal tissue for CCT2 (Fig. 7A). To determine if CCT2 levels
increased with disease progression in these two lung cancer subtypes, we grouped TMA
cores according to their TNM classification (Figure 7C-D) or stage (data not shown) and
found no statistically significant differences among the groups analyzed. Essentially,
CCT2 levels were higher than normal lung in these lung cancer subtypes and independent
of stage or grade. To investigate if CCT2 levels correlated with survival in lung cancer
patients, we used the publicly available Kaplan-Meier plotter database to generate
survival data in all lung cancer patients that expressed high levels of CCT2 mRNA. We
found that there was a statistically significant correlation (p = 0.0031) between decreased
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survival of grade III lung cancer patients and CCT2 expression, with a 30-month
difference in survival between the higher expression patient cohort and the lower
expression patient cohort (Fig. 7E). These results were confirmed with the TCGA
database.
We and others previously reported a correlation between high levels of CCT
subunits and disease progression in breast [18], hepatocellular and colonic carcinoma,
and gallbladder squamous/adenosquamous carcinoma [70]. To our knowledge, however,
no other groups have published a correlation between lung cancer and CCT levels. To
address this gap, we selected this cancer type to investigate further

SCLC cell lines express varied levels of CCT2, CCT4, and CCT5 subunits and were
susceptible to killing by CT20p.
About 95% of SCLC patients have TP53 mutations [71]; therefore, as
representative cell lines for our studies, we chose four SCLC cell lines containing
common TP53 mutations and one SCLC cell line with wild-type TP53 (Table 5). To
assess CCT expression in the SCLC cell lines, we determined the basal protein levels of
the subunits CCT2, CCT4, and CCT5 by immunoblot (Fig. 8A-C). The levels of assayed
subunits were normalized to total protein by staining the membrane prior to blocking.
Figure 8D provides a representative image of the membrane stained for total protein. The
cell line NCI-H1048 had the highest level of all five cell lines assayed for CCT subunits
(Fig. 8A-C). In contrast, NCI-H719 had the lowest level of CCT2, CCT4, and CCT5 (Fig.
8A-C). The levels of CCT subunits in cell lines NCI-H1882, NCI-H1417, and NCI-
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H1105 were in between those of the highest and lowest SCLC cell lines (Fig. 8A-C). For
a qualitative analysis of relative levels of the assayed CCT subunits, we normalized the
signal from all cell lines to the signal from cell line NCI-H1048 for each CCT subunit
assayed. We then combined the data into one graph to aid visualization (Fig. 8E). It is
important to note that this comparison is only qualitative since different antibodies were
used to detect each subunit. The relevant knowledge we gained from these experiments is
that we can now detect protein level differences of each CCT subunit among the selected
cell lines. As a quality control check for our protein lysates, we also assayed basal levels
of wild-type (WT) or mutant p53 in these cell lines and found that NCI-H719 cells had
the highest and NCI-H1417 cells had the lowest levels of mutant p53, which confirmed
the data set available at the ATCC website (Fig. 9A-B).
Our previous published work showed that CT20p is selectively cytotoxic to breast
cancer cells, and that modulating the levels of CCT2 by inhibition or overexpression
regulated the susceptibility of cells to killing by CT20p [18]. Hence, it is likely that
CT20p’s primary mechanism of action is inhibition of CCT. To deliver CT20p to cells,
we encapsulated the peptide in nanoparticles made from a hyperbranched polyester
polymer (CT20p-NPs). These nanoparticles are approximately 80 nm in diameter,
monodispersed and spherical as we have shown in our previous publications [14, 15, 18,
19]. Peptide loading efficiency was estimated to be 0.15 g CT20p per mg polymer.
These nanoparticles are negatively charged and we confirmed uptake by all SCLC cells,
using nanoparticles loaded with the fluorescent dye DiI (Fig. 10). All cells were treated
with 75 and 150 g/mL of CT20p-NPs (based on polymer amounts) for 48 hours and
live/dead cells detected with two probes to assess intracellular esterase activity (Calcein
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AM) for live cells and plasma membrane integrity (ethidium homodimer) for dead cells.
Live cells fluoresced green, while dead cells fluoresced red. The cell line most
susceptible to CT20p treatment at the two doses tested was NCI-H1048 (Fig. 11B), which
also displayed the highest levels of all three CCT subunits (Fig. 8A-C). The cell line with
the lowest amount of all three CCT subunits, NCI-H719, was also killed by CT20p
treatment but to a lesser extent (Fig. 11E). Interestingly, the only cell line with WT p53,
NCI-H1882, had the second lowest levels of CCT subunits but was also highly
susceptible to CT20p treatment (Fig. 11A) This suggests that loss of p53, a CCT client
protein, could contribute to cell death in this line. Hence, total levels of CCT may not
always be as important as the outcome of CCT protein folding activity. The two cell lines
with high CCT2 levels but lower levels of the other subunits, NCI-H1417 and NCIH1105, were susceptible to CT20p, more so for NCI-H1105 (Fig. 8C-D, Fig.11C-D).
These results indicate that while all SCLC cell lines were killed by CT20p-NPs, those
like NCI-H1048 that upregulated multiple CCT subunits were more sensitive to killing by
the peptide. We also observed that in a number of these cell lines, the cells tended to
aggregate or cluster (NCI-H719, NCI-H1882), which also decreased upon treatment with
CT20p (Fig. 11E,A). This is important as we have shown that CCT inhibition through
CT20p reduces actin and tubulin, which are cytoskeletal components that are CCT client
proteins [15, 18]. Additionally, of the three SCLC cell lines with the highest levels of
CCT subunits (NCI-H1048, NCI-H1417, and NCI-H1105), those derived from metastatic
sources were more susceptible to killing by CT20p than those derived from a primary
tumor source. These results are summarized in Table 7.
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CCT2 levels correlate with STAT3 levels in SCLC patient tissues.
CCT is responsible for folding ~5-10% of the cell’s proteome [24] and many of
its client proteins are involved in oncogenesis; however, the full CCT interactome
remains to be discovered [60]. To determine whether CT20p treatment results in
decreased CCT client proteins, we evaluated STAT3 because this transcription factor is
frequently involved in oncogenesis [72] and its biosynthesis and activity is directly
regulated by CCT [28]. To demonstrate a correlation between STAT3 and the levels of
CCT2 in tumors from SCLC patients, we used TMAs containing SCLC tumor cores
(Table 3) for analysis of both CCT2 and STAT3. We found that the levels of STAT3
consistently correlated with CCT2 (Fig. 12A) in most SCLC patient tumor tissues.
Representative images of two STAT3/CCT2 pairs showing lower score (score 2 and 3)
and high (score 4) are in Figure 12B. Next, we assayed total STAT3 protein levels in
SCLC cell lines and determined that STAT3 was detectable in all five cell lines with the
highest levels in NCI-H719 (Fig. 14A). To investigate the effect of CT20p-NPs treatment
on the levels of total STAT3, two adherent SCLC cell lines that were most sensitive to
the peptide, NCI-H1882 and NCI-H1048, were subjected to treatment with the peptide
for 16 hours and 6 hours respectively. These times were chosen in order to obtain enough
viable cells for high quality cell lysates. Protein lysates were not effectively recovered
from SCLC cells treated with CT20p-NPs beyond 16 hours, indicating that most cells
after treatment are likely dead or dying. CCT2 and STAT3 protein levels were
normalized to total protein to control for any proteolysis in the CT20p-treated cells. We
found that in both SCLC cell lines, STAT3 levels decreased significantly, supporting the
notion that CT20p could be inhibiting the protein-folding activity of CCT and causing
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loss of client proteins like STAT3 (Fig. 13A). We also noted that the levels of CCT2
itself also decreased, but to a lesser extent. That CT20p could cause destabilization and
cause the loss of CCT subunits is intriguing and indicates that more needs to be learned
about the regulation and formation of the CCT complex.
We also treated the SCLC cell lines with a STAT3 inhibitor (STAT3 inhibitor VI)
that binds to the SH2 domain and prevents STAT3 phosphorylation. Previous published
studies showed a reduction in tumor cell growth in vitro at doses < 100 M [73, 74].
SCLC cells were treated for 48 hours at 50 and 100 M and viability assessed as in
Figure 11. We found that other than the SCLC line, NCI-H719, the SCLC cells were
minimally affected by the STAT3 inhibitor (Fig. 14B). This suggests that CT20p was
more effective at reducing STAT3 levels and killing cells than a typical STAT3 inhibitor
that targets only the phosphorylation and activation of the transcription factor.

Immortalized and actively dividing cells have high levels of CCT2.
To examine the broader effect of CT20p treatment on other cell lines, we selected
three immortalized non-cancer cell lines that are typically used as controls for testing
chemotherapeutics [75]. The AC16 and THLE-2 cell lines are used to examine cardio
and liver toxicities. Based on our previously published work, the normal breast cell line
MCF-10A was also selected. We first determined the basal levels of CCT2 (Fig. 15A)
and STAT3 (Fig. 15B) and included two SCLC cell lines, NCI-H1048 and NCI-H719, for
comparison since NCI-H1048 had the highest level of CCT2 and NCI-H719 had the
lowest (Fig. 8A). Note that Figure 15C contains a representative image of one of the blots
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used for relative quantification of the target levels as well as the total protein stain used
for normalization. AC16 and THLE-2 cells had levels of CCT2 that were even higher
than one of the SCLC cell lines, NCI-H719 (Fig. 15A). This was expected since both
AC16 and THLE-2 cell lines were immortalized using SV40 oncogene [66, 76]. SV40
inhibits p53 and Rb1, inactivation of which are hallmarks of SCLC. The conditional
inactivation of these alleles in mice was sufficient for the mice to develop SCLC [77].
We also observed a similar trend of high CCT2 levels when cells like the immortalized
lung cancer cell line, BEAS-2B (data not shown), and normal bronchial epithelial
(NHBE) or fibroblast cells (NHLF) (Fig. 16) were actively replicating in cell culture,
likely due to the need for increased CCT client proteins like cyclins. Since it is known
that NBE cells can cause phenotypic changes when co-cultured with cancer cells [78]
future studies will investigate CCT levels under co-culture conditions and in senescent
versus dividing cells to determine the involvement of the chaperonin in modulating the
behavior of normal and cancer cells. In this regard, in our previous work [18], we found
that MCF-10A cells can undergo spontaneous epithelial-to-mesenchymal (EMT)
transformation and that transformed cells exhibit higher levels of CCT2 and are
susceptible to CT20p treatment as shown in Figure 15D. Treatment with CT20p proved
toxic to these immortalized cells given their high expression levels of CCT2 (Fig.
15A,D). Normal tissues, on the other hand, are not immortalized with oncogenes or
actively dividing, so levels of CCT2 were lower, as we observed with normal lung tissue
(Fig. 15E) and tissues from other organs such as the heart and liver (Fig. 15E). To
examine any potential toxicities that could result from CT20p treatment, we performed a
dose escalation study in mice. We observed no significant alternations in the liver and
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kidney function of mice and all clinical chemistry values were within reference ranges
(Fig. 17), nor were any changes in weight, blood in urine or necrosis of organs observed
(Fig. 17). Hence, these studies suggest that CT20p’s susceptibility is based on the
expression levels of CCT, as well as the activity of the chaperonin. This could establish a
therapeutic window that could be exploited to develop an effective treatment strategy.
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Figures
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Figure 6: Effects of high levels of CCT2 in hepatocellular, prostate and colon
cancers
(A, E and I) Levels of CCT2 were assayed in human tumor tissue samples of
(A)hepatocellular, (E) prostate and (I) colon cancer by immunohistochemistry (IHC) as
described in Supplemental Methods and Materials. Representative images of different
staining intensities are shown for (D) hepatocellular (200X) and (H) prostate(400X)
tissues. Images of stained tissues as well as analysis of staining intensity were performed
by a pathologist For staining analysis a score between 0-4 was give following a scheme
previously published in Bassiouni et al (2016). Significance was calculated in reference
to normal tissue. p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. (B, F)
Survival data for patients with high and low levels of CCT2 were queried using the
TCGA database trhough cBioPortal ( repository can be found in Supplemental Methods
and Materials). (B) Kaplan-Meyer plot for HCC patients showing that duplication of
CCT2 gene decreases survival.(F) Kaplan-Meyer plot for prostate cancer patients
showing that genomic alterations in CCT2 decreases median survival rate by half. (C,G
and J) Survival data for patients with high levels of CCT2 was queried using The Human
Protein Atlas database showing that (C) in HCC patients with high levels of CCT2 the 5year survival rate is 25% compared to 52% in patients with low levels of CCT2. (G) In
prostate cancer, patients with high levels of CCT2 have a 5-year survival rate of 93% and
patients with low levels of CCT2 have 99% survival rate. (J) In colonic carcinoma, the 5year survival rate for patients with high levels of CCT2 is 69% versus 54% for patients
with low levels.
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Figure 7: Analysis of CCT2 staining in lung cancer patient tissue
(A) The levels of CCT2 were assayed in human tumor tissue samples of different lung
cancer subtypes by immunohistochemistry (IHC) as described in Materials and Methods.
Tissue cores were analyzed by a pathologist according to stain intensity and given a score
between 0-4 as previously published in Bassiouni et al (2016). Significance was
calculated in reference to normal lung tissue. (B) Representative images of stained human
tissue microarrays (TMAs) shows the elevated levels of CCT2 in both squamous cell
carcinoma and small cell carcinoma compared to low levels in normal lung tissue. (C)
Small cell lung cancer (SCLC) samples were grouped according to TNM score (T1/T2
and T3/T4) and stain intensity for CCT2 was compared between them. Significance
indicated is in reference to normal lung tissue. (D) Squamous cell lung carcinoma
(SqCLC) was also grouped by TNM score (T1/T2 and T3/T4) and CCT2 stain intensity
was compared. Significance indicated is in reference to normal lung tissue. (E) KaplanMeier plot of lung cancer patients based on CCT2 expression. The survival graph was
generated using publicly available database (KM plotter; www.kmplot.com). Data
analysis was restricted to patients with grade III lung cancer (n=77). * = p<0.05, ** =
p<0.01, *** = p<0.001, **** = p<0.0001
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Figure 8: Levels of CCT subunits are detected in SCLC cell lines
Lysates corresponding to five SCLC cell lines were subject to immunoblot analysis for
(A) CCT2, (B) CCT4 and (C) CCT5. The bar graphs below each corresponding blot,
shows their relative levels for all five cell lines. Relative quantification was calculated by
normalizing antibody specific signal to signal obtained from total protein. (D) PVDF
membrane stained for total protein using Revert (LI-COR). (E) Graph showing relative
values of the three assayed CCT subunits in each SCLC cell line. * = p<0.05, ** =
p<0.01,
*** = p<0.001,
**** = p<0.0001. Blot images are representative
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Table 3: Sample sizes for lung tissue cores analysis
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Table 4: Sample sizes for liver, colon and prostate tissue cores analysis
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Figure 9: Levels of p53 in SCLC cell lines
Cell lines from the ATCC SCLC p53 Hotspot mutation panel, used in this study, were
assayed for p53 levels as quality control. (A) Total soluble lysate corresponding to
indicated cell lines (five human SCLC cell lines and an immortalized lung breast
epithelial cell line) were assayed for p53 levels (red band). GAPDH was used as loading
control (green band). (B) Bar graph showing relative quantification of p53 levels which
were normalized to GAPDH levels as described in Supplemental Methods and Materials.
(C)Amino acid change due to genomic mutations found in TP53 for each cell line. All
mutations resulted in “loss of function”
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Figure 10: CT20p NPs co- localize with SCLC cells
DiI
dye
(1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine
Perchlorate)
encapsulated in HBPE-nanoparticles were delivered to viable SCLC cells as described in
Materials and Methods. Cells were imaged after 24 hours for fluorescent signal
indicative of nanoparticle uptake. Column (A) Phase contrast images(4X) (B) Phase
contrast(4X)/ TexasRed merged image.
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Figure 11: CT20p is cytotoxic to SCLC cell lines
Five SCLC cell lines were subject to CT20p treatment at 75 μg/ml or 150 μg/ml for 48
hrs as described in Methods and Materials. Untreated control received medium only.
Calcein-AM and ethidium homodimer were added to cell cultures prior imaging to
indicate live (green) and dead (red) cells respectively. Representative images of (A) NCIH1882, (B) NCI-H1048, (C) NCI-H1417, (D) NCI-H1105 and (E) NCI-H719 are shown
for untreated control and the two doses used. Signal obtained using GFP filter (indicative
of live cells) was divided by signal detected using TexasRed filter (indicative of dead or
damaged cells) for each cell line. Bar graphs adjacent to each corresponding cell line
show the normalized ratios (%live/dead). Cytotoxic effects can be observed by an overall
decrease in green signal concomitantly to an increase in red signal. * = p<0.05, ** =
p<0.01, *** = p<0.001, **** = p<0.0001

46

Figure 12: In SCLC patient tissue, levels of CCT2 correlate with levels of client
protein Stat3
(A-B) TMA containing human SCLC tissue was stained for CCT2 and Stat3 in parallel as
described in Methods and Materials. Tissue cores were analyzed by a pathologist
according to stain intensity as described previously. (A) Pie chart indicates the number of
cores which received equal scoring for CCT2 and Stat3 staining, as well as cores which
received scores that differed by 1 (no cores received scores that differed by more than 1).
(B) Representative images of corresponding CCT2 and Stat3 stained TMA cores D2 and
E7 respectively. Images were provided by the pathologist at 200X (D2 pair) and 400X
(E2 pair).
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Figure 13: CT20p treatment decreases levels of Stat3 in SCLC cell lines
(A) Cell lines NCI-H1882 and NCI-H1048 were treated with 75 μg/ml CT20p-NPs for 16
hours and 6 hours respectively, at which point cells were trypsonized and lysates made.
Soluble lysates of untreated cells (cultured in parallel with treated cells and lifted at the
same time) were immunoblotted for CCT2 and Stat3. Bar graphs indicate relative levels
of CCT2 and Stat3 in control and treated cells calculated as in Figure 8A-C. (B) Image of
stained PVDF membrane showing total protein corresponding to the samples blotted.
Signal obtained from total protein was used to normalize CCT2 and Stat3 signal. * =
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001
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Figure 14: SCLC cell lines Stat3 inhibition
(A) Immunoblot showing relative levels of Stat3 in the five SCLC cell lines. Levels of
Stat3 shown were normalized to total protein. Calculations are described in Methods and
Materials. (B) Five SCLC cells lines were treated with Stat3 inhibitor IV at 50μM and
100μM as described in materials and methods. The cell line the highest levels of Stat3,
NCI-H719, had the most significant response. Analysis was performed by averaging
triplicates and significance was calculated as described in Methods and Materials. * =
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001
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Figure 15: Immortalized cell lines are high expressers of CCT2
(A-B) Immunoblot of the indicated immortalized cell lines alongside two SCLC cell lines
for (A) CCT2 and (B) STAT3. (C) PVDF membrane stained for total protein, used for
normalization of band intensity after antibody probing. (D) Viability of immortalized cell
lines after 48 hours treatments with CT20p-NPs at indicated and control was assessed
using Calcein-AM and ethidium homodimer to indicate live and dead cells respectively.
(E) The levels of CCT2 were assayed in tissue from normal organs by IHC as described
in Materials and Methods. Representative images of stained TMAs of liver, heart and
lung shows minimal levels of CCT2 detected.
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Figure 16: Primary lung cells have high levels of CCT2
Normal human bronchial epithelial cells (NHBE) as well as normal human lung
fibroblasts (NHLF) were assayed for levels of CCT2 and susceptibility to CT20p. (A)
Levels of CCT2 in primary lung cells were high compared to SCLC cell lines. Levels are
shown as percent of the highest signal (HNLF) and normalization was performed as
described previously. (B) NHBE cells were treated with CT20p as described in Methods
and Materials and cytotoxicity detected using Live/Dead (Promega). Signal from 3 wells
were averaged as means and standard error. Per well, four overlapping quadrants were
imaged and stitched using Gen5 software. Images shown are representative of the
experiment.
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Figure 17: Results from blood chemistry, urinalysis, weight and histology from mice
treated with CT20p-NPs
Three male and three female nude mice (6-8 weeks old) were treated with five doses (2.4
mg/kg, 4.8 mg/kg, 9.6 mg/kg, 19.2 mg/kg, 38.4 mg/kg) of CT20p-NPs over a two week
period. Treatments were performed on Days 0, 3, 7, 10 and 14 and mice were euthanized
14 days after the last treatment. (A) Serum of treated mice was sent to Idexx for testing
for the chemical chemistry panel which assesses kidney and liver function. No statistical
differences were observed between control and NP-treated mice. Reference table contains
normal clinical chemistry values adapted from the Animal Care Website at the University
of Arizona. (B) The weight of mice during treatment was determined at the specified time
points. (C) Urine analysis was performed using dipstick during treatment at four time
points as indicated in the table. Results from a representative mouse are shown. (D)
Histology of treated mice liver and kidney showing no signs of necrosis. Representative
images are shown.
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Table 5: Information on cell lines used in this study:

Normal Tissue
Immortalized

Small Cell Lung Cancer

Supplemental Table S2
Cell line

Tissue

Source

Key characteristics/ mutations

Lot
number

NCI-H1882
(ATCC CRL-5903)

Lung

Metastatic site:Bone marrow

Adherent cell line/ RB1 mutation

58136167

NCI-H1048
(ATCC CRL-5853)

Lung

Metastatic site: Pleural
effusion

Adherent cell line - cells grow in colony and
can form clusters/ RB1, TP53 mutations

62784665

NCI-H1417
(ATCC CRL-5869)

Lung

Primary

Suspension cells - grow in floating clusters/
RB1, TP53 mutations

62007515

NCI-H1105
(ATCC CRL-5856)

Lung

Metastatic site: Lymph node

Suspension cells - grow in floating clusters/
TP53 mutations

63374473

NCI-H719
(ATCC CRL-5837)

Lung

Metastatic site:Bone marrow

Suspension cells - grow in floating clusters/
RB1, TP53 mutations

62007616

THLE-2
(ATCC CRL-2706)

Liver

Liver

Epithelial cells transformed with SV40
large T antigen [1].

64258509

MCF-10A
(ATCC CRL-10317)

Breast

Breast epithelial

Breast epithelial cells, derived from human
fibrocystic mammary tissue spontaneously
immortalized [2].

64066742

Cardiomyocyte

Primary cells from human ventricular
tissue, were fused with SV40 transformed,
RD1606008
uridine auxotroph human fibroblasts,
devoid of mitochondrial DNA [3].

AC16 (SCC109)

Heart

Table summarizes information pertaining to cell lines used in the experiments in the main manuscript. Information about tissue
of origin, source (primary versus metastatic sites for tumor derived cell lines), key characteristics and lot number are provided.
Relevant publications regarding the immortalized cell lines used are provided.
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Table 6: Comparison of CCT2 levels, CT20p susceptibility, tumor source, and key genes mutated
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This table summarizes results on experiments using the five SCLC cell lines obtained from CCT2 blots found in Figure 2,
CT20p susceptibility found in Figure 3, tumor source, culture type (suspension versus adherent) and key genes containing
mutations. The criteria for “high, medium and low levels” are summarized on the table itself. In short, for CCT2 levels, figure
2E was used. Cell lines with signal about 70% were classified as “high”, and below 30% as low, if in between, they were
considered “medium”. For CT20p susceptibility, average values obtained for untreated, 75μg/ml and 150μg/ml were plotted in
prism and using linear regression, the IC50 value for each cell line was determined. If the extrapolated IC50 was below
75μg/ml, susceptibility was considered high, if above 121μg/ml, susceptibility was determined to be low, if in between, cells
were considered partially susceptible to CT20p treatment.
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Discussion

In this study, tissues and cells from various cancers and normal organs were used
to investigate CCT as a potential biomarker and therapeutic target in cancer treatment.
We assessed CCT2 subunit protein levels across prostate, liver, and lung cancer tissue
specimens and found that CCT2 expression levels correlated with disease progression in
liver and prostate cancers, and CCT2 levels were significantly higher in lung carcinomas
as compared to normal lung tissue independent of disease stage. We also showed that
CCT2 levels were low in normal heart, liver, and lung tissues. These findings build upon
our previous discoveries in breast and prostate cancer in which CCT2 levels were
elevated as compared to non-disease tissues. Using SCLC cell lines, we demonstrated
susceptibility to killing by our putative CCT inhibitor, CT20p, which proved more
effective than a STAT3 inhibitor, and the resulting reduction of CCT client proteins (e.g.,
STAT3) in part addressed the mechanism of action for CT20p.
CCT belongs to the family of group II chaperonins that are found in eukaryotic
cells and archaea and consists of eight paralogous subunits that differ mainly at the apical
domains [61]. Unique to CCT is the formation of hetero-oligomeric complexes and the
use of an ATP-dependent conformational change to control the opening/closing of a
built-in lid [22, 61]. Hence, subunit diversity and sequential substrate binding generates
multiple substrate binding sites that, when coupled to the lid closing mechanism, endow
CCT with a flexibility to fold many more proteins than its bacterial counterparts [26].
This broad range of protein substrates means that 5-10% of newly synthesized proteins
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may require CCT for folding [24], but also that only part of the CCT interactome has
been discovered. Given our findings of elevated CCT expression across cancer types, it is
likely that CCT is responsible for folding more of the cell proteome in cancer or
transformed cells than in normal cells. There also seems to be a selectivity for CCT
subunits based on cancer types. For example, CCT3 and CCT8 were overexpressed in
hepatocellular carcinoma (HCC) [39, 72, 79, 80] and the proteins were detected in the
plasma from patients, suggesting that CCT3 could be used as a biomarker for screening
HCC. We and others found that CCT2 was elevated in breast cancer [18, 41] as well as
in gall bladder carcinoma [70]. In the current study, in addition to HCC and prostate
cancer, we also found that CCT2 was increased in SCLC and in advanced stages of
SqCLC. Understanding why cancers are selective for CCT subunits may require a better
understanding of the basis of CCT substrate recognition as well as the discovery of new
classes CCT substrates, such as those up-regulated in cancer cells.
As a possible CCT inhibitor, CT20p is one of the first. While arsenic was shown
to inhibit CCT function and impair both actin and tubulin filaments [81], other than
CT20p, only N-iodoacetyl-tryptophan (I-Trp), a synthetic small molecule, has been found
to disrupt the interaction between CCT and tubulin, causing apoptosis through an ER
stress-dependent mechanism [82, 83]. In contrast to I-Trp, CT20p does not cause death
through a traditional apoptotic mechanism [14], which can be downregulated in cancer
cells;

rather, its inhibitory effects could extend to multiple client proteins that are

essential for cancer progression [84].

Hence, inhibitors of protein folding have

therapeutic value since their inhibition can decrease the pool of oncoproteins that cancer
cells depend on. As an example, inhibitors of the heat shock protein family (HSPs),
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Hsp90 or Hsp70, showed significant efficacy in pre-clinical studies [85]. The Hsp90
inhibitor, Ganetespib, proved effective in SCLC cell lines, causing cell cycle arrest and
caspase-3 dependent apoptosis [86]. However, human clinical trials in non-small cell
lung cancer (NSCLC) with molecularly unselected patients were disappointing. While
some promising results were observed in a cohort of patients with ALK-rearrangements,
HSP inhibitors overall did not perform as expected from the pre-clinical data. The
reasons for this could be that inhibition of HSPs may trigger a protective heat shock
response through activation of heat shock transcription factor 1 (HSF1) and GRP78,
which blocks the apoptosis of cancer cells. Alternatively, the level of HSP inhibition
achieved in patients could have been insufficient to kill tumor cells [87]. Patients also
developed resistance to Hsp90 inhibition due to activation of RAF/MEK/ERK or
PI3K/AKT/MTOR pathways, requiring the need for combination approaches to make
Hsp90 inhibitors work [88]. We anticipate that inhibition of CCT with CT20p may not
result in similar problems because we have no evidence of induction of a heat shock
response, such as the membrane translocation of GRP78 (data not shown). Further, the
use of nanoparticles to deliver CT20p to tumors can achieve therapeutically relevant
doses [14, 15, 19]. Our data also suggest that CT20p could knock out pathways—such as
those induced through STAT3—that are linked to growth and survival signaling; hence,
resistance activated by these pathways may not develop.
STAT3, which regulates the expression of genes involved in cancer progression,
is an attractive target for inhibition in SCLC since it is found in primary SCLC tissues
and in SCLC cell lines [89]. While a number of STAT3 inhibitors have been developed,
most either inhibit the kinases that phosphorylate and activate STAT3 or they prevent the
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formation of STAT3 dimers through disruption of the protein’s SH2 domains. Drugs,
like the antibiotic doxycycline, inhibit STAT3 in lung cancer cells at the cost of severe
side effects in patients like nausea, vomiting and diarrhea, rash and sensitivity to sun
[90]. While there are many STAT3 inhibitors, few have moved into clinical trials and
none to the clinic. Reasons for this failure are unknown but could be explained by the fact
that most STAT3 inhibitors target the dimerization or phosphorylation domains;
therefore, unphosphorylated STAT3 is unaffected and available for activation [91]. Since
CCT is essential for the synthesis, refolding, and activity of STAT3 [28], inhibitors of
CCT should also reduce the levels of total STAT3. Our data show that in SCLC cell
lines, CT20p reduced STAT3 levels, while these same cell lines were resistant to killing
with a STAT3 inhibitor. In fact, only one SCLC cell line was susceptible to the STAT3
inhibitor and also had the highest levels of STAT3. This cell line was also killed by
CT20p, likely due to the loss of STAT3 along with other CCT client proteins.
Cancers like SCLC are challenging diseases to treat and are typically
diagnosed at advanced stages. Systemic treatments are not curative [43]. Molecular
targeted therapies are promising, despite requiring patients to be pre-screened, but only a
few targets, like ALK, are associated with clinically relevant inhibitors (e.g., Crizotinib)
and patients frequently relapse [87]. Our research suggests that therapeutically targeting
CCT with inhibitors like CT20p could have benefits for SCLC patients. As shown in our
studies, CCT subunits are overexpressed in SCLC as well as in advanced stages of other
cancers. We anticipate that each patient will likely have their own unique CCT
interactome based on the oncogenes that drive their cancer. The products of many of
these oncogenes—such as STAT3, KRAS, or MYC—are CCT substrates; hence, each
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patient whose cancer overexpresses CCT could be treated without the need of molecular
subtyping the downstream substrates. So whether a patient’s tumor is driven by STAT3,
MYC, Notch or a combination, they could still be treated with a CCT inhibitor since the
chaperonin is essential for these proteins to reach functional status. Our approach, using
the nanoparticle platform to deliver CT20p, has the potential to reach therapeutic doses in
tumors and minimize off-site accumulation. CT20p treatment also has promising use in
combination approaches with other drugs. Trials with checkpoint inhibitors in SCLC
resulted in some durable responses [9], generating interest in agents like CT20p that
could make cancers immunogenic or sensitive to radiation therapy
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Introduction

Breast cancer is one the most commonly diagnosed cancer types and the second
leading cause of death in women [42]. Tissue biopsy is typically used to confirm
diagnosis and classify the tumor according to histological grade, using parameters such as
the Nottingham Histologic Score and pathologic staging (TMN). Such classification,
while needed for prognosis, does not always provide information on useful markers that
can guide targeted therapies. In contrast, molecular classification of breast cancer allows
for a patient specific treatment plan, which yields improved patient outcome. There are
five breast cancer molecular subtypes, which are classified according to the levels of
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor
receptor 2 (HER2), claudin and EGFR: claudin-low, basal-like/triple negative, Her2
enriched, luminal A and luminal B [92]. Cancers with such markers can be treated with
drugs like Tamoxifen that blocks the effects of estrogen or Herceptin (trastuzumab)
which works against HER-2 positive cancers. While these treatments are successful, the
need still exists for the discovery of new therapeutic targets for cancers lacking hormone
receptors or to improve the use of current therapies in combination approaches.
Triple negative breast cancer (TNBC) tumors are aggressive and are associated
with poorer prognosis compared to the ER-positive subtypes [93]. TNBC is marked by
the absence of ER, PR and Her2 receptor, therefore, patients diagnosed with this type of
breast cancer are not eligible for hormone therapy or anti-HER2 agents. TNBC represents
about 17% of all breast cancer cases and is marked by genomic instability, heterogeneity,
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high recurrence rates and increased risk of metastasis. Patients diagnosed with TNBC
have limited therapeutic options and a much lower survival rate. To address this issue, we
previously reported the development and efficacy of CT20p, a cancer specific cytotoxic
peptide [18]. In the same work, we provided compelling evidence that the intracellular
target of CT20p is the chaperonin containing TCP1 (CCT) or T-complex 1 ring protein
(TRiC). CCT is a macromolecular, evolutionarily conserved complex composed of two
stacked rings, back-to-back, with each ring being comprised of eight distinct subunits
CCT1-CCT8 or CCTα-θ [94]. All eight subunits share the same basic structure
containing an equatorial ATP binding domain, an apical substrate binding domain and an
intermediate domain, linking the other two domains [62]. CCT substrates are sequestered
into a central chamber, formed by the two stacked rings, where protein folding occurs in
an ATP-dependent fashion [62, 63]. About 10% of the proteome is thought to interact
with CCT [24] including CCT’s obligate clients, the cytoskeletal proteins actin and
tubulin, and cell cycle regulators Cdc20 and Cdh1 [22, 94, 95]. Other client proteins
include, PLK1 [96], cyclin E [34], the von Hippel Lindau tumor suppressor [31], Stat3
[28], p53 [33] and MYC [26]. Considerable evidence suggests that CCT has a role in
oncogenesis and tumor progression [97]. The genes coding for the eight CCT subunits are
amplified in a variety of cancers [64]. CCT1 and CCT2 are essential for breast cancer cell
survival and are linked to driver oncogenes responsible for tumorigenesis in breast cancer
[41]. Our previous work shows that CCT2 is significantly overexpressed in invasive
ductal breast carcinoma (IDC), in TNBC cell lines, such as MDA-MB-231 and MDAMB-436 [18], and in prostate cancer cell lines [19], which suggests that CCT2 levels
could indicate increased disease severity.
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For the work presented here, we further investigated the role of CCT2 in
tumorigenesis to better understand its contribution to cancer progression. Using the
CRISPR/Cas9 system, we generated breast cancer cell lines with partial inhibition of
CCT2 (full inhibition was lethal) and using a lentiviral over expression system, we
produced breast epithelial cells with increased levels of CCT2. As a result, we detected
changes in tumorigenicity and key CCT client proteins like STAT3. These findings
indicated that CCT could be a driver of breast cancer through selective expression of
subunits like CCT2 that confer increase protein folding activity to provide essential client
proteins needed by cancer cells to survive, grow and transform. Hence CCT2 could be a
new molecular marker for breast cancer and target for novel cancer therapies.
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Materials & Methods

Cell lines and culture conditions
Cell lines used were MDA-MB-231 (ATCC HTB-26) triple negative breast
cancer cells and MCF10A (ATCC CRL-10317™) breast epithelial cells. MDA-MB-231
cells were low passage cells cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Corning) supplemented with 10% FBS (Gemini) and 1% Penicillin-Streptomycin
(Corning). MCF10A cells were low passage cells cultured in Mammary Epithelial Basal
Medium (MEGM-Lonza) supplemented with bovine pituitary extract (BPE), human
epidermal growth factor (hEGF), hydrocortisone ( all from MEGM bullet kit - Lonza)
and 1% Penicillin-Streptomycin (Corning). MDA-MB-231 transfected with CRISPR
gRNA 3 plasmid (GenScript) were cultured in the same medium as WT MDA-MB-231
with the addition of 0.5 μg/mL puromycin dihydrochloride (ThermoFisher). The
MCF10A cells transfected with the lentiviral plasmid were cultured in the same medium
as the WT MCF10A with the addition of 1 μg/mL puromycin dihydrochloride
(ThermoFisher). All cells were grown in a humidified incubator at 37° C with 5% carbon
dioxide.

Immunohistochemistry
Small cohort tissue microarray (TMA) was obtained from Florida Hospital
(IRBNet# 748165). Large cohort TMAs containing normal breast tissue and breast cancer
tissue at various disease stages were commercially acquired (BR8013 and BR8017, US
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Biomax) and contained associated information about the tissue type, TNM score, tumor
grade, and stage. TMAs were stained for CCT2 using anti-CCTβ antibody (LS-B4861;
LifeSpan Biosciences) and for STAT3 using anti-Stat3 antibody (ab32500; Abcam).
Antibodies were diluted 1:100 in Antibody Diluent (Leica). Staining of tissue arrays was
performed using a Bond-Max Immunostainer (Leica), with an epitope retrieval buffer of
EDTA pH 9.0 (Leica). Polymer Refine Detection reagents (Leica) were used, which
include a hematoxylin counterstain. Scoring of staining was performed by a surgical
pathologist as previously published [18].

Plasmids and primers
The CRISPR knockout CCT2 CRISPR guide RNA 3, Clone ID: C27761, Vector:
pSPCas9 BB-2A-Puro (PX459) v2.0 was purchased from GenScript. The lentiviral
plasmid pLV[Exp]-EGFP:T2A:Puro-EF1A>{hCCT2[ORF023792]*/FLAG} for CCT2
overexpression was purchased from Vector Builder by Cyagen Biosciences. Envelope
vector pMD2.G (Addgene 12259) and packaging vector psPAX2 (Addgene 12260) were
provided by Didier Trono through Addgene plasmid repository. PCR primers used for
CCT2 knockdown efficiency were Forward CACTGCCCCTTTAACTGTCA and
Reverse AGCTGCTGGATTGTCAACAC from Eurofins.
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Lentiviral transduction
Lentiviral

plasmid

pLV[Exp]-EGFP:T2A:Puro-

EF1A>{hCCT2[ORF023792]*/FLAG} for CCT2 overexpression (Cyagen Biosciences),
envelope vector pMD2.G (Addgene 12259),and packaging psPAX2 (Addgene 12260)
were transfected into 293T cells using transfection solution (105 μM Tris, water, 98 mM
CaCl2, and 1X HEPEs-buffered saline). Supernatants containing the virus were harvested
24 and 48 hours post-transfection. The virus was concentrated in 15 mL Beckman
Ultraclear tubes at 4° C 70000 x g for 1.5 hours then resuspended in RPMI 1640
(Corning). MCF10A cells were plated in 6 well plates and transduced with 50X virus
stock the following day in MEBM as described above with 8 μg/mL polybrene
(Millipore). The following day cells were washed twice with 1X phosphate-buffered
saline (Corning) and medium replaced with MEBM containing 1 μg/mL puromycin.
CCT2 overexpression was monitored by tracking GFP signal in the transduced cells.

CRISPR/Cas9 MDA-MB-231 CCT2 knockdown cell line generation
CRISPR knockout CCT2 CRISPR guide RNA 3, Clone ID: C27761, Vector:
pSPCas9 BB-2A-Puro (PX459) v2.0 was designed by the Zhang lab and purchased
through GenScript. The plasmid was transformed into DH5α E. coli and maxiprepped
using Invitrogen PureLink HiPure Plasmid Filter Purification Kit Catalog #K2100-15 and
Invitrogen PureLink HiPure Precipititator Module Kit Catalog #K2100-21 following the
included protocol. MDA-MB-231 cells were plated in 6 well plates overnight and
transfected the following day using Mirus Trans-IT® X2 Transfection reagent. 48 hours
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following transfection the cells were split and placed under selection with 0.5 μg/mL
puromycin in DMEM.

CCT2 knockdown efficiency
Measurement of CCT2 genomic cleavage performed using Life Technologies
GeneArt Genomic Cleavage Detection Kit (Cat# A24372) following the included
protocol. MDA-MB-231 CCT2 Knockout cells were collected and pelleted for each
sample and lysed according to protocol. Using the lysate, PCR was performed around the
region of interest using primers: Forward CACTGCCCCTTTAACTGTCA and Reverse
AGCTGCTGGATTGTCAACAC. The PCR product was confirmed to be present and of
the correct size by running on 1.5% agarose gel with control primers to validate the kit.
Next the PCR product underwent cleavage assay according to the protocol and the final
product run on a 1.5% agarose gel. Intensity of each band was analyzed using ImageJ
software to measure relative intensities. The gel image was captured as a TIF and
converted to an 8-bit black and white image. A histogram of each lane was generated and
the area of the curve and percent intensity was captured using the wand tool. The relative
density was calculated by relative density = % of sample/ % of standard.

Immunoblots
Antibodies for immunoblots include: anti-TCP-1 beta (Millipore,clone F39 P7
F11 MAB10050 mouse monoclonal (1:1000 WB) , Abcam anti-TCP-1 delta ERP8495(B)
ab129072 rabbit monoclonal (1:1000 WB), Abcam anti-TCP-1 epsilon EPR7562
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ab129016 rabbit monoclonal (1:1000 WB), Abcam anti-STAT3 antibody E121-21
ab32500 rabbit monoclonal (1:1000 WB), Santa Cruz anti-p38α (C-20) rabbit polyclonal
(1:1000 WB), LI-COR IRDye 680 CW Goat anti-Rabbit IgG (1:10000 WB)and LI-COR
IRDye 800 CW Goat anti-Mouse IgG (1:10000 WB). For lysate preparation, cell pellets
were washed in 1X PBS prior freezing and stored at -80° C for at least 30 minutes. Cells
were lysed by resuspending in ice-cold NP-40 Lysis Buffer (50 mM K+ HEPES pH 7.5,
150 mM NaCl, 1% NP-40, 1 mM EDTA) containing 1X protease inhibitors
(ThermoScientific) on ice for 10-15 minutes. Lysates were centrifuged at 12000 x g for
15 minutes at 4° C to pellet cellular debris. Supernatant recovered was mixed with 4X
Orange G loading dye (LI-COR) supplemented with 10% β-mercaptoethanol (Gibco) and
heated at 99° C for 10 minutes. Proteins were resolved by SDS-PAGE and transfered to
PVDF membrane (Immobilon-FL Millipore IPFL00010). Before membrane blocking,
total protein was measured using the REVERT Total Protein Stain (LI-COR) and
detected by NIR fluorescence at 700 nm (LI-COR Odyssey). The membrane was blocked
for 1 hour (1% fish gelatin in TBS-T with 0.1 mM EDTA) followed by overnight
incubation with primary antibody, at 4° C. The membrane was incubated with secondary
antibody for 1 hour at room temperature then imaged on the LI-COR Odyssey.
Quantification was performed using LI-COR Image Studio software and signal
normalized to total protein signal. Normalization was calculated by dividing the total
protein signal of each lane by the lane with the highest signal to gain the Lane
Normalization Factor (LNF). The quantified signal for each protein band was divided by
each LNF to gain the normalized signal. Each sample had three technical replicates.
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Migration assay
Cellular migration was measured using Oris Migration Assembly Kit (Platypus
Technologies). Stoppers were placed in each well and cells seeded around the stoppers.
The stoppers were removed after 2 hours and wells were imaged on the Cytation 5
(Biotek). The cells were incubated for an additional 15 hours. The control cells were
stained using CellTrace CFSE stain (ThermoScientific) for 20 min at 37° C then all cells
were imaged as previously. The images were analyzed using Gen5 Software for mean
GFP signal within the plug. The wells were quantified by subtracting the pre-migration
signal from the post-migration signal.

In vivo experiments
Female nude (nu/nu) mice used in these experiments were obtained from Charles
River Laboratories. Mice were allowed to acclimate for one week after arrival, prior
undergoing orthotopic implantation of cells. Each mouse received 800,000 cells into the
right mammary fat pad in a 50:50 solution of PBS and Matrigel Matrix (Corning Cat#
354248). One group of mice received MDA-MB-231 cells (n=3) (tumor control mice)
and another group of mice (n=3) received MDA-MB-231 CCT2 knockout cells. Mice
were monitored for 60 days and once the tumor was large enough to be detected, caliper
measurements were taken three times per week. The formula used for tumor volume
measurements was length (mm) x width (mm) x 0.5). All animal work followed the study
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protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of Central Florida

Statistical analysis and data mining
For scoring analysis of TMAs one-way ANOVA was used to compare mean
scoring between the different groups defined by various tissue parameters. Tukey’s
multiple comparison test was used to compare significance between individual groups.
Survival data was analyzed using Sidak’s multiple comparison test. Calculations were
performed with GraphPad Prism software (GraphPad). Statistical significance was
defined as p < 0.05. Breast cancer patient survival data in the current study is available in
the Kaplan-Meier Plotter (KMPlot) repository [67, 68] at:
http://kmplot.com/analysis/index.php?p=service&cancer=breast

Results

Increased CCT expression correlates with lower overall survival in breast cancer
patients
There are eight genes (cct1-8) that encode the subunits that form the CCT protein
folding complex. To determine whether breast cancer patient survival correlated with
increased gene expression of individual CCT subunits, we interrogated the breast cancer
database available in the Kaplan-Meier plotter (n=3951). We found that while increased
expression of all the subunits correlated with decreased patient survival, the most
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statistically relevant results (p< 0.0026) were achieved for CCT2 (Fig. 18A-B).

A

difference in survival of over 44 months was noted for patients that were high expressors
of CCT2 compared to low expressers of CCT2 (Table 7). These results support our
previous findings using The Cancer Genome Atlas (TCGA) database that increased
expression of the CCT2 subunit is associated with decreased breast cancer patient
survival [18] .We also found that CCT2 copy is increased across cancer cells lines
(Project Achilles) and that CCT2 is an essential gene (Fig. 19A-C).

CCT2 levels are higher in tissues of breast cancer patients when compared to normal
breast tissue and correlate with levels of STAT3.
We next examined a small cohort of archival tumor tissues (n=20) from patients
with invasive ductal carcinoma (IDC) from a local hospital for protein levels of CCT2 as
well as one of the CCT client proteins, STAT3. While CCT levels varied from low to
high irrespective of cancer grade or stage, an almost 100% correlation between CCT2 and
STAT3 levels was observed (Fig. 20A). We expanded this study to include commercially
available tumor tissues from patients with advanced breast cancer, stage II or greater
(n=160). Tumor tissues representative of scoring for CCT2 and STAT3 staining are
shown in Figure 20D. We observed that CCT2 and STAT3 levels were low in normal
tissues and increased in stage II or III breast cancer (Fig. 20B-C). When directly
comparing CCT2 and STAT3 staining, we found that over 50% of the tumors had equal
scores, that 37.6% of the tumors has scores that differed by only 1 score point and that
11.4% of the tumors differed by 2 or more score points (Fig. 20E). This indicated that
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88.6% the tumors had comparable levels of both CCT2 and STAT3, suggesting that more
CCT2 could confer increased protein folding activity and provide more client proteins
like STAT3 to cancer cells.

Decreased levels of CCT2 leads to decreased levels of STAT3, while increase in CCT2
leads to increased STAT3
Based on the studies showing that CCT2 is an essential gene for cancer cells (Fig.
19B-C), we opted for a knockdown of CCT2 in MDA-MB-231 breast cancer cells using
CRISPR-CAS-9 technology. We previously showed that these cells had high levels of
CCT subunits as compared to the breast epithelial cell line, MCF-10A [18]. Using a
genomic cleavage assay, we achieved a 32% decrease in CCT2. This cell line showed a
corresponding decrease in CCT2 protein and as well as a decrease in STAT3 (Fig. 21B).
Next, using a lentiviral system, we generated a stable MCF-10A cell line that
overexpressed FLAG-tagged CCT2. We confirmed both expression of the FLAG tag and
increased CCT2 in the cell line and observed an increase in STAT3 (Fig. 22). Together
these results, support that CCT2 is driving the levels of client proteins like STAT3 and
could underlie the mechanism by which CCT promotes cancer progression.

Increased expression of CCT2 stimulated cell migration, while decreased levels of CCT2
reduced tumor growth in mice
The overexpression of CCT2 in the non-tumorigenic breast epithelial cells,
MCF10A, increased migration capabilities in these cells (Fig. 23A-B). MCF10A cells are
immortalized but they are unable to form tumors in mice, these cells are sensitive to
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confluency, nutrients and environment and can undergo spontaneous epithelial-tomesenchymal (EMT) transitions, a process that can also be induced by treatment with
TGF-beta [98]. MDA-MB-231 cells are highly tumorigenic in mice. To determine if
decreasing levels of CCT2 in the MDA-MB-231 influenced tumorigenicity, we used
CRISPR/Cas9 with a gRNA targeting CCT2 to partially inhibit gene expression (Fig. 21).
Cells were injected orthotopically in the mammary fatpad of female nude mice and tumor
growth compared between wild-type (WT) MDA-MB-231 cells and CCT2 inhibited
MDA-MB-231 cells. We found that tumors lacking CCT2 grew slower by 14 days (Fig.
25) and were 2-5 fold smaller after 8 weeks (Fig. 25). These results show that even a
partial loss (~32%) of a single CCT subunit, like CCT2, is sufficient to significantly
impair tumor cell migration and tumor growth, indicating that inhibiting this protein
folding complex could be an effective therapeutic approach.
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Figures

Figure 18: High CCT expression levels significantly decrease survival in breast
cancer patients
Survival data in breast cancer patients showing that higher expression of all CCT
subunits correlates with lower survival rates. (A) Bar graph of survival data showing that
CCT3 levels have the highest effect on overall survival, but CCT2 levels have the most
significance between high and low levels. (B) Kaplan-Meier plots of breast cancer
patients based on the expression level of each CCT subunit. Numbers used to generate
data is also on table 7. The survival graph was generated using publicly available
database. Cohort size: 3951 patients (KM plotter; www.kmplot.com).
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Table 7: Effect of high and low expression of each CCT subunit in survival of breast cancer patients

CCT subunits

Low expression cohort
(months)

High expression cohort
(months)

Significant?

Summary

Adjusted P Value

TCP1

216.7

171.43

No

ns

0.0594

CCT2

216.7

137

Yes

**

0.0026

CCT3

78.48

38.4

No

ns

0.1032

CCT4

216.7

160.28

Yes

*

0.0194

CCT5

216.7

161.43

Yes

*

0.0216

CCT6A

228.85

184.04

No

ns

0.0624

CCT7

216.7

168.5

Yes

*

0.0438

CCT8

216.7

163.46

Yes

*

0.0264

Numbers used to generate data shown in Figure 18.
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Figure 19: CCT2 copy number and CCT2 essentiality in MDA-MB-231 cells
Data and graphs obtained using publicly available databases (A) CCT2 copy number in
cancer cell lines. Data from the Cancer Cell Line Encyclopedia (CCLE). Breast cancer
cell lines have the highest copy number. (B-C) Data on CCT2 and essentiality in common
cell lines (B) Achilles knockdown of CCT2 vs copy number and (C) Achilles knockdown
of CCT2 versus mRNa expression showing essentiality of MDA-MB-231 cells [99].
Entrez ID: 10576 https://figshare.com/articles/AguirreMeyers/3420907
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Figure 20: CCT2 levels are significantly higher in breast cancer tissues than normal
breast tissue and significantly correlates with STAT3 levels
Human tissue derived from breast cancer patients were stained for CCT2 and Stat3 using
immunohistochemistry. (A) Bar graph showing a strong correlation between levels of
CCT2 and Stat3 on breast cancer tissue. Data obtained from local cohort samples (n=20).
(B-C) Breast cancer containing medium to advanced stage breast cancer TMAs were
purchased from USBiomax (cohort n=160). (B) CCT2 and (C) Stat3 staining scores.
Tissue cores were analyzed by a pathologist according to stain intensity and given a score
between 0-4 as previously published in Bassiouni et al (2016). (D) Graph of staining
score results. Representative images of breast cancer TMA stained for CCT2 and Stast3
indicating scores of 0, for normal breast tissue and scores of 1-3 for tumor tissue. All
images were taken using 400X magnification. (E) Pie chart with percentage of scores
that were identical (51%), differed by 1 point (37.6%) and by 2 or more points (11.4%).
Significance indicated in graphs are in reference to normal tissue.). * = p<0.05, ** =
p<0.01, *** = p<0.001, **** = p<0.0001
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Figure 21: Knockdown of CCT2 in MDA-MB-231 cells
(A) The levels of CCT2 are reduced after stable transfection with CRISPR/Cas9 plasmid
guide RNA 3. (B) Bar graph showing relative protein levels. CCT2 and stat3 levels are
decreased after CRISPR/Cas9 (C) Total protein used for normalization. (CRISPR/Cas9
by A. Showalter and blots by the author)
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Figure 22: Overexpression of CCT2 increases the levels of CCT client protein
STAT3.
Representative CCT2 and STAT3 blots of the control parental line and CCT2
overexpression line show increased protein levels under normal growth conditions (n=1).
(B) The relative protein levels of CCT2 and STAT3 are both increased after normalizing
the signal to total protein. (C) Representative blot of the total protein used to normalize
the CCT2 (left) and STAT3 (right) blots. (Transfection performed by A. Showalter and
blots performed by the author)
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Figure 23: CCT2 overexpression cells migrate faster than the control line
Cells were plated around 2mm plugs and allow to adhere for 2 hours. The plugs were
removed and the cells were allowed to migrate for 15 hours before imaging. Reference
wells for T=0 had the plugs removed prior to staining with CFSE and subsequent
imaging. Fluorescent images of the reference wells were taken for T=0 and samples wells
for T=15. (A) Control cells (n=4 wells) showed some migration after 23 hours. (B) CCT2
overexpressing cells (n=4 wells) showed significantly more migration than the control
cell line. (C) The mean GFP signal of cell within the 2 mm plug was measured with Gen5
software using the following formula: (signal post-migration – signal pre-migration). The
results were analyzed using Graphpad Prism with a paired T test with p<0.05. (By A.
Showalter)
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Figure 24: Overexpression of CCT2 in normal breast epithelial cells induces a
change in morphology
Representative images taken by Zeiss Axio Imager by phase contrast at 10X
magnification. (A) MCF-10A, normal breast epithelial cells grow in small patches and
remain mostly elongated. (B) CCT2 overexpression cells, as indicated by +CCT2,
become more cuboidal and grow in a more confluent monolayer.
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Figure 25: Knockdown of CCT2 decreases tumorigenicity of MDA-MB-231 cells in
mice
Female nu/nu mice received either control (n=3) or CCT2 knockdown cells (n=3)
injected into the mammary fat pad. Tumors were allowed to grow and were measured by
calipers three times a week starting once the tumor was palpable. (A) Over a period of 60
days post-surgery, the control tumors grew large, with one being terminated early
following the protocol. The CCT2 knockdown (KD) tumors remained smaller than the
controls throughout the experiment. (B) The control tumors started to grow significantly
earlier than the CCT2 knockdown tumors. Control tumors started to grow approximately
18 days post-surgery while CCT2 knockdown tumors did not start growing until
approximately 30 days post-surgery.
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Discussion

Using tools for genetic engineering, we generated cell lines in which expression
of cct2 was inhibited or increased to show that the CCT protein folding complex was
essential for the process of tumorigenesis. Full loss of CCT2 in breast cancer cells was
lethal, and a partial loss resulted in reduced client proteins like STAT3 and decreased
tumor growth in mice. Increased expression of CCT2 altered the morphology of breast
epithelial cells, increased STAT3 levels, and promoted a migratory phenotype. In support
of CCT2 as a promising therapeutic target, we observed increased levels of CCT2 protein
in tumor tissues from patients with advanced breast cancer, which highly correlated with
STAT3 levels. In contrast, CCT2 levels were undetectable to low in normal breast
tissues. Increased gene expression of CCT2 also correlated with decreased breast cancer
patient survival. These findings support further investigation of CCT2 as a promising
biomarker for breast that could have diagnostic as well as prognostic potential.
Group II chaperonins like CCT are found in the cytosol of archaea (e.g.
thermosomes) and eukaryotes. CCT is evolutionarily conserved with multiple gene
duplication events producing the eight subunits that form the two-ring complex[100]
Each subunit has a unique position in the ring and substrates recognition is likely
mediated through combinations of hydrophilic and hydrophobic interactions. What
remains poorly understood is the level of redundancy or moonlighting for each CCT
subunit. We observed that loss or overexpression of a single subunit, CCT2, was
sufficient to alter the activity of the complex as reflected by the levels of client proteins
like STAT3 and functional consequences such as migration and tumorigenicity. These
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results suggest that individual CCT subunits are unique and could have multi-functions
that are exploited by cancer cells. In support, others have shown that mutations in
individual CCT complexes have divergent effects on cells. For example, mutation of
CCT2 in yeast cells resulted in slower growth that was associated with a cell cycle defect,
while mutations in CCT7 resulted in protein aggregations [101]. Such studies indicate
that CCT subunits may each have unique roles related to substrate specificity but also the
possibility that each subunit may have “moonlighting” functions independent of the
complete complex. This is supported by our previous work and those of others using
small interfering RNAs to inhibit individual CCT (iCCT) subunits, which suggested that
iCCT subunits may have roles beyond protein folding, such CCT4 (epsilon) in the
polymerization of F-actin [102] or CCT2 in promoting cancer cell growth [18, 41]
That CCT has a prominent role in oncogenesis is evident in the increasing number
of reports documenting the activity of the protein folding complex in the signaling
pathways critical to malignancy such as the STAT family of transcription factors [28] as
we show herein. Other CCT substrates important for cancer cell growth include cycle
regulators and cytoskeletal proteins as well as proteins directly related to oncogenesis
such as VHL and p53 Hence distinct CCT subunits are overexpressed in different
cancers. In addition to our findings that CCT2 is highly expressed in advanced breast
cancer, others have found CCT2 elevated in gall bladder carcinoma [70], colorectal
adenocarcinoma [103] and heptacellular carcinoma [40]. Several groups found that CCT3
expression was diagnostic in hepatocellular carcinoma [72, 79, 80], as well as CCT8 [39].
While this list is not extensive, it clearly demonstrates the growing trend that individual
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CCT subunits are highly expressed in different cancers and could be important
therapeutic targets.
The discovery of CCT’s role in cancer progression has significant clinical
implications in the development of personalized medicine for cancer therapy. Our data
indicates that the CCT2 subunit could be a new biomarker for breast cancer that may be
prognostic and help reveal when cancers progress and it could also be used as a
companion or complementary diagnostic to guide therapies. In this regard, our lab
developed a CCT inhibitor based on the capacity of an amphipathic peptide called CT20p
[14, 104] to impair the chaperonin’s activity. Much of the functional consequences of
loss of CCT2 that are reported herein, such as decreased tumorigenicity, also result upon
treatment with CT20p [15, 18]. Hence being able to manipulate the levels of CCT2 in
cells, as we have shown, not only establishes the importance of this protein folding
complex in oncogenesis but also provides a tool by which we can further address the
pressing questions on the roles of individual CCT subunits and the possible consequences
(or lack of) of CCT inhibition upon normal, healthy cells. The biology of chaperonins
like CCT is complex but its understanding could reveal new targeted approaches for
breast cancer therapy.
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CHAPTER 4: SMALL MOLECULE SCREEN DEVELOPMENT
USING TRIPLE-NEGATIVE BREAST CANCER CELLS

Preface

The first complete draft of this chapter was written by A.C.C. Comments from
A.K were incorporated as it appears here.

Manuscript in preparation
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Introduction

High throughput screens (HTS) are the backbone of drug discovery in the
pharmaceutical industry as well as among academic researchers [105]. This type of
screen encompasses testing a large number of compounds on a daily or weekly basis, for
their biological effects. There are many types of HTS libraries including small peptides,
small molecules, natural products and synthetic building blocks. In a target based
approach, four crucial steps need to be considered in HTS design: target selection and
validation; chemical hit and lead generation; lead optimization to identify a clinical drug
candidate; and finally hypothesis‐driven, biomarker‐led clinical trials [106]. However,
phenotypic screens are also used in instances where the target in unknown or targeted
assays are not conducive with HTS.
Based on data previously published by our lab, the mammalian chaperonincontaining TCP1 (CCT) is an ideal candidate for target based drug discovery. We have
showed that CCT is the intracellular target for CT20p, a cytotoxic peptide discovered by
our lab [15, 18, 84, 107]. CCT is a macromolecular complex, composed of two rings
stacked back-to-back, forming a barrel-like structure in which unfolded substrates are
sequestered away from the cytosol until they reach their native conformation [62]. Each
ring is composed of eight distinct, paralogous, subunits (CCT1-8). We identified targets
of CT20p in a pull-down assay using biotin-CT20p. Proteomic analysis indicated CT20p
interacts with seven out the eight CCT subunits [18]. We have also showed that in breast
cancer cells, CT20p cytotoxicity correlates with CCT levels [18]. In addition, CCT levels
have been shown to be higher in multiple cancers when compared to normal tissues [64]
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The approach we developed and report here does not directly screen for CCT
inhibitors, but it can be classified as target driven/phenotypic hybrid. Our primary, in cell
assay uses a triple-negative (TNBC) cell line that stably expresses luciferase, therefore,
decrease in luminescence can be caused by CCT inhibition, luciferase folding inhibition
by direct interaction with the compound or cell death by an unrelated mechanism.
Regardless of the MOA of the compound, every compound that met our luminescence
signal decrease threshold (> 70% signal loss) criteria was selected as a hit compound and
moved to the next screen.
In this manuscript, we report the results for a pilot screen involving a 2100
compound library focusing on assay development, optimization, hit compounds and lead
identification.

Materials and Methods

Cell culture and conditions
MDA-MB-231/Luc cell line was purchased from Cell Biolabs, Inc. (AKR-231)
and MDA-MB-231 cells were obtained from ATCC. The firefly luciferase gene was
stably transfected into the cell line and placed under the CMV promoter. Cells were
cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS
(Gemini). MCF-10A (ATCC CRL-10317) cells were cultured in Mammary Epithelial
Cell Growth Media using MEGM bullet kit (Lonza). All media contained 1% antibiotic
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antimycotic solution (Corning). Cells were grown in a humidified 37C incubator with
5% carbon dioxide.

Reagents and small molecule library
D-luciferin (Goldbio) was dissolved in 1X PBS at 15 μg/ml, filter sterilized using
0.22 μm filter (Millipore) and stored in small aliquots in -20°C. Staurosporine InSolution
(Calbiochem) stock concentration was 1mM, in DMSO.
The 2100 compounds were purchased from Asinex and distributed in a 384 plate
format. Compounds were in DMSO and the stock concentration was 10mM. Plates were
stored in -80°C.

Assay format, optimization and z’factor calculation
Cell seeding density: The screen was performed using 96 well plates (white,
PerkinElmer). To determine optimal seeding density and signal linearity, MDA-MB231/luc cells were seeded in two sets of triplicates at 1500, 3000 and 5000 cells per well.
After 24 hours, spent medium was replaced with fresh medium containing 0.1μg/mL Dluciferin. Plate was wrapped in aluminum foil and luminescence signal measured after 10
minutes. This was repeated at the 48 hour time point as well.
Controls: For this pilot screen, the positive control for luminescence signal loss
was staurosporine, used at 0.5μM final concentration (Fig. 27A)
Assay validation: The z’ factor determines the quality of the assay, taking into
account only the controls used in the assay [108]. The z’ factor values range from 0 to 1,
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values above 0.5 are considered excellent. We have determined the z’ factor to be 0.611
for our assay.
Secondary screen: To determine the effect of hit compounds on non-tumorigenic
cells, MCF10A cells were seeded at 10,000 cells per well and treated with 10M for 48
hours. Viability was determine using CellTiter-Glo (Promega).

Results

Primary screen identified 24 hits in a 2100 compound library
Using a library composed of 2100 small molecules, we developed and optimized
an in cell assay selecting for molecules that decreased luminescence signal by 70% or
more in MDA-MB-231/luc cells. Compounds were tested at 10M in duplicate wells.
Each test plate contained duplicates of positive and negative controls and signal from test
compounds were normalized to internal controls (Fig. 27B).
Both luciferase and luciferin are CCT clients, if the compound inhibits CCT,
luciferase and luciferin will not fold properly and there will be a decrease in
luminescence compared to the untreated control. Figure 28 summarizes the rationale for
the assay. We identified 24 compounds that met the criteria.
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Secondary screen
For a hit to move to the next phase of testing, it cannot have cytotoxic effects on
normal cells. For that, we tested the 24 hit compounds on the non-tumorigenic MCF-10A
cell line using the same concentration as in the primary screen. Only minimal cytotoxic
effects were observed (Fig. 30A).

Lead compound
To identify the lead compound, we tested each of the 24 hits using an extended
dose range from 2.5μM-40M. Standard MDA-MB-231 (non-luc) cells were seeded as
described in materials and methods. Only one “hit”, the lead compound, killed the 231
cells in a dose dependent manner with and IC50 ~5M (Fig. 30B).
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Figures

Figure 26: MDA-MB-231 cell seeding density optimization
On a 96 well white plate 1500, 3000 and 5000 cells per well were seeded in triplicates.
Luciferin was added and signal measured (A) 24 hours or (B) 48 hours. (C) Graph
showing linear relationship between cell number and signal detected using our approach.
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Figure 27: Assay plate set up showing position of positive and negative controls
(A) Signal from negative (untreated cells) and positive (staurosporine) controls.
Staurosporine is a protein kinase inhibitor and it causes cell death through a canonical
apoptotic pathway. (B) Only the inside wells were used for this assay to avoid edge
effects. The plate set up includes both controls in every plate so data normalization is
performed per plate.
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Figure 28: Summary of the assay rationale
The TNBC cell line, MDA-MB-231/luc stably expresses luciferase. Both luciferin and
luciferase are folded by CCT. If CCT is inhibited by the small molecule in the screen, it
will not fold luciferase properly and luminescence signal will be low. Each plate has both
the positive and negative controls. The data is normalized to the internal controls per
plate. Small molecules that caused luminescence signal loss by >70% we considered hits.
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Figure 29: Representative structures identified in the screen.
A) Structure identified as the lead compound B) Six of the 24 compounds identified in
the screen.
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Figure 30: Lead compound secondary assays results
(A) Bar graph showing the percent survival of normalized signal of lead compound
effects at 10μM, on control and TNBC cell lines using CellTiterGlo (B) Dose response
of lead compound on MDA-MB-231/luc cells
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Discussion

Our drug screening strategy to identify novel CCT inhibitors was validated using
a pilot 2100 compound library. We rationalized that because both luciferase and luciferin
are known to be folded by CCT, although they are not obligate clients [94], if the
compound inhibits CCT, we will observe a decrease in luminescence compared to the
untreated control. The initial screen identified 24 hit compounds , equivalent to ~10% of
the library [109], based on loss of luminescence. We expected that a few of these could
be chaperonin inhibitors. Secondary screens revealed which of these compounds was not
toxic to immortalized breast epithelial cells but still killed triple negative breast cancer
cells. Counter screens showed which of these compounds did not induce a heat shock
response but did trigger the membrane translocation of calreticulin (not shown). Based on
these assays, we identified one hit that matched our criteria for a possible CCT inhibitor.
To date, other than our CT20p peptide, no general use CCT inhibitors have been
identified. There are only a few reports of CCT inhibitors based on hindering a specific
interaction with a known client (e.g. tubulin [81, 82]) that have limited application.
Hence our study would be the first to discover a CCT inhibitor that could have clinical
use for multiple cancers. Disrupting molecular chaperones as a form of cancer therapy
was first explored for HSP90. Hsp90 has received the most attention as a possible
therapeutic target because it is upregulated during oncogenesis [83, 86, 88]. A number of
small molecules and natural product inhibitors of HSP90 advanced to clinical trials. The
best known of these are geldamycin derivatives [110]. However, problems with induction
of protective heat shock response and the inability to achieve therapeutic doses hampered
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these trials [111]. Another approach for targeting proteins essential for cancer cells, is to
inhibit the proteasome. Pathways for protein folding and ubiquitin-mediated proteolysis
have a number of points of commonality. Proteasome inhibitors, like Veldcade, are
currently used in the treatment of multiple myeloma [112]. Benefits were also observed
with combination approaches of protein folding and proteasome inhibition, hence, our
CCT inhibitor could be used to improve existing therapeutics in combination approaches.
The typical screens used to identify agents that impair molecular chaperones are
cell-based and involve loss of a chaperone-dependent activity. In one study, a v-srcluciferase fusion was used as reporter and hits included HSP90 inhibitors, ubiquitin
pathway inhibitors, histone deacetylase inhibitors and others, revealing one of the
challenges of this approach when seeking an inhibitor that could impact many
downstream substrates [113]. Hence, it becomes important to generate a strategy, as we
described herein, to move from a general screen to one that is more specific for CCT. As
example, one group developed a method to purify the complete human CCT complex (all
eight subunits) from HeLa cells. To confirm activity of the complex, a luciferase
refolding was performed [114]. However, a more rigorous test was needed to ensure that
the complex being isolated was indeed CCT, so an assay to measure aggregation
suppression was also included [94]. However, this assay is tedious and time consuming
and does not lend itself to high throughput. Our solution was based on characterizing the
biological effects of CCT inhibition observed upon treatment with CT20p, such as the
membrane translation of CRT and absence of GRP78 membrane translation, which can
be assessed by flow cytometry. The latter was especially important as a counter screen,
because most HSP90 inhibitors can cause GRP78 membrane exposure as part of
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protective heat shock response. Future screens could also incorporate use cell lines that
stably overexpress or inhibit CCT subunits as well as employ in silico drug screen
technology to identify classes or families of compounds that can dock at the substrate
bindings sites of CCT.
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CHAPTER 5: CONCLUSIONS

Preface

This chapter was composed entirely by A.C.C.
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CCT2 levels are significantly higher in prostate, hepatocellular, breast and lung
cancers compared to normal tissues, indicating CCT as a potential biomarker in these
cancers. CT20p is cytotoxic to SCLC cells but not normal lung tissue, therefore targeting
CCT with CT20p in SCLC is a promising therapeutic approach. CCT levels are high in
immortalized cell lines or cells lines that have undergone EMT, but the same is not
observed in normal human tissue, therefore immortalized or transformed cell lines cannot
be used as control for CT20p experiments. When CCT is inhibited, levels of client
proteins, such as STAT3 decreases, indicating CCT targeting has the potential to inhibit
many pathways involved in oncogenesis. Partially knocking out CCT2 in MDA-MB-231
cells, a highly tumorigenic triple negative cell line, is sufficient to decrease
tumorigenicity potential in nude mice. Overexpressing CCT2 in immortalized breast
cells, increases migration and causes morphology to change, two characteristics of cells
that have undergone EMT and causes levels of client proteins, such as STAT3, to
increase.

CCT2 levels is a biomarker in many cancers
Using patient tissue microarrays containing 80-120 cores each, we determined
CCT2 levels in a large number of samples in prostate, colon, liver, breast and lung
cancers by immunohistochemistry. We were also able to correlate CCT2 levels with
stage, severity, and histological characteristics in these TMAs, allowing us to conduct a
broad analysis of CCT2 in the most common cancers affecting the population today. We
found that CCT was significantly higher in advanced tumors when compared to normal
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tissue. SCLC stood out by having the highest CCT2 levels among the cancers analyzed in
our study. We used publicly available genomic databases and found that all CCT subunits
are expressed at higher levels in breast cancer and that higher levels correlate with
decreased survival. The CCT subunit with the most significant effect on patient survival
was CCT2, which indicates that this subunit has an essential role in breast cancer
progression, which is validated by previous work published by us and others [18, 41, 70].

Targeting CCT with CT20p in SCLC is a promising therapeutic approach
Using five SCLC cell lines, we showed that CT20p is cytotoxic in a dose
dependent manner and that cytotoxicity levels vary among cells lines, indicating that
there’s a therapeutic window which allows for effective eradication of tumor cells while
sparing non- cancerous ones.
Client proteins, such as STAT3, also respond to CCT inhibition to different
degrees in a cell line dependent fashion. Targeting CCT is a rational approach because
cancer cells express and rely on the chaperonin more heavily than normal cells. Rapidly
proliferating cells, such as during development and spermatogenesis, have higher levels
of CCT than non-proliferating cells, as it has been shown in a previous study done using
mice [115, 116]. Using siRNA to deplete CCT causes cell cycle arrest in Swiss 3T3
mouse fibroblasts indicating CCT has an essential role in cell cycle progression[102]. In
this same study, CCT’s folding activity was modulated by using an antibody against
CCT5 which caused loss of cell motility and cytoskeletal disorganization [102]. Similar
effects were observed in studies by our lab on CT20p effects on breast cancer cells [18].
109

Other CCT inhibitors include arsenic and N-iodoacetyl-tryptophan (I-Trp) [81]. Arsenic
inhibits CCT and impairs actin and tubulin filaments [81, 85]. I-trp is a synthetic small
molecule derived from iodoacetamide capable of interrupting the constitutive βtubulin/CCT2 interaction eliciting caspase-dependent signaling which leads to cellular
apoptosis [82, 83]. An advantage of CT20p, is that cell death is caused independently of
the canonical apoptotic pathway [14], which is often downregulated in tumor cells,
instead, CT20p prevents folding of many tumor essential proteins therefore, halting
tumor progression [84]. Targeting CCT, a chaperonin responsible for folding many
oncogenic proteins, is advantageous in the sense it decreases the pool of essential proteins
required for tumor progression.

CCT2 plays a role in oncogenesis
The TNBC cell line MDA-DB-231 is a highly tumorigenic and commonly used to
investigate growth and metastasis of human breast cancer in vivo, by xenograft
transplantation in immunocompromised mice [117]. By partially knocking out CCT2
using CRISPR/Cas9, tumor development was delayed by about 2 weeks compared to
control cells. We were unable to obtain complete CCT2 knock out cell lines because full
loss of CCT2 in this cell line was lethal. In addition to decreasing tumor growth in mice,
partial loss of CCT2 also resulted in reduced client proteins like STAT3. These results
agree with previous work that found CCT to be overexpressed in cancer cells compared
to non-cancerous cells, with notably high expression in MDA-MB-231 cells [64],
suggesting this cell line has a higher CCT dependency for growth and survival.
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Overexpressing CCT2 in immortalized, untransformed breast epithelial cells
induced morphological changes and increased migration, a phenotype also observed in
this cell line when it undergoes EMT, suggesting that CCT could have a role as a driver
of oncogenesis.
The role of CCT complex in oncogenesis has not been extensively explored yet,
but there is an increasing trend in recently published work suggesting that CCT’s role in
cancers could be cancer specific. In addition to our findings on CCT2 overexpression in
breast cancer, others have reported CCT2 to be elevated in gall bladder carcinoma [70],
colorectal adenocarcinoma [103] and hepatocellular carcinoma [40]. Also in HCC, CCT3
was determined to be diagnostic in hepatocellular carcinoma [72, 79, 80], as well as
CCT8 [39, 40]. Together, these data suggest that there might be a CCT subunit/cancer
type correlation that should be further explored since understanding this relationship
would help elucidate the process of oncogenesis and ultimately lead to better therapies.

The search for small molecules inhibitors of CCT
We developed an in cell, luminescence based assay for rapid screen of small
molecules able to inhibit CCT and/or luciferase folding in TNBC cells. The assay was
considered optimal based on the high z’factor obtained (z’factor =0.6) [108]. In a period
of 2 months, 2100 small molecules were screened, in duplicates, yielding 24 hits. The
number of hits obtained by this assay further validates our approach, since robust HTS
assays are expected to yield 10% of the total number of screened molecules as hits.
Secondary screens identified one lead compound which caused cell death in a dose
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dependent manner in TNBC cells but only minimally affected immortalized breast
epithelial cells. Unfortunately, the structure associated with the lead compound was
inaccurate and we were unable to continue further characterizing of the lead molecule.
Nonetheless, in this study, we developed and validated a high throughput screen assay
that is relatively simple, cost effective and scalable, consequently establishing a new
platform for the screening of larger libraries for potential inhibitor of CCT. Future studies
will focus on developing an in vitro companion and/or secondary assay focused on CCT
activity. Luciferase folding assay is commonly used to test CCT activity [61, 94], as a
companion assay, it would be possible to screen for CCT inhibitors by combining results
from the in vivo with the in vitro components by setting more lax thresholds and only
considering the compounds above both thresholds as “hits”. Alternatively, the in vitro
component would serve as a secondary assay, for inhibitors of CCT that directly contact
at least one of the eight subunits, thus, only true CCT inhibitors would continue further
characterization. The approach we used to screen for CCT inhibitors in vivo using TNBC
cell lines that stably express luciferase can be adapted to any cancer cell line capable of
stably expressing luciferase, thus, the impact of this work expands well beyond breast
cancer and could impact an array of different cancer types.

Concluding remarks
The discovery of CCT’s role in cancer progression has crucial clinical
implications in the development of personalized medicine for cancer therapy. TNBC and
SCLC, both aggressive, highly metastatic cancers that currently lack efficient treatments,
have the potential of being detected earlier by using CCT2 levels in biopsies and treated
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effectively by targeting CCT as a therapeutic approach. Other cancers, such as prostate
and hepatocellular can also benefit from CCT targeted therapies. Therefore, the findings
presented in this dissertation provide a broad impact in the cancer field of research which
can be translated into the clinic and ultimately on patients affected by these cancers.
Because CCT subunits have different specificities and reports have shown they have
different roles in several different disease states, understanding the role of each CCT
subunit in normal cells as well as their role in different cancers is imperative and it will
allow for rational drug design, tailored to each cancer type, with improved targeting
capabilities and decreased off target effects. As an alternative, the development of
medium and high- throughput screens aimed to identify CCT inhibitors in many cancers,
such as the one presented in this dissertation which used TNBC cells, could yield novel
therapeutics in a faster time-scale. Altogether, the work presented in this dissertation
demonstrates the feasibility of CCT as a biomarker in many cancers, especially SCLC,
the use of CT20p as a cancer therapeutic and that CCT2 has an essential role in cancer
progression, significantly contributing to overall body of knowledge in the cancer field.
Future work is focused on elucidating the inhibitory mechanism of CT20p at the cellular
level and further exploring CCT as a molecular target for therapeutics.
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